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Effects of Dietary Fats on Mechanisms of Adipose Expansion and Function 
Allison Marie Wing 
2021 
Obesity, defined as the excessive accumulation of white adipose tissue 
(WAT), is a global pandemic and increases risk of many other pathologies. 
However, in vivo molecular mechanisms of adipocyte formation, or adipogenesis, 
during obesity and high-fat diet (HFD) consumption are still being understood. 
WAT can expand either through the proliferation of adipocyte precursors (APs) 
and their differentiation to form new adipocytes (adipogenesis) or through the 
increased size of adipocytes (hypertrophy). To study how dietary fats impact 
adipose expansion, mice were fed custom HFDs, each containing a different fat 
source, and adipogenesis and hypertrophy were quantified. This screen 
illustrated how dietary fats may bias the WAT toward expanding primarily through 
increased adipocyte size or number. This dietary fat screen was also 
instrumental in identifying oleic acid as a molecular signal inducing adipocyte 
precursor (AP) activation and proliferation. Oleic acid increased adipogenesis in 
vitro through Akt2 signaling and induction of lipogenesis. Using RNA sequencing 
of APs from mice fed HFD, downregulation of LXRα signaling was consistently 
identified in adipose tissue depots that demonstrate an adipogenic response to 
HFD. LXRα phosphorylation was identified as a modulator in the proliferative 
response to HFD, with dephosphorylation of LXRα resulting in enhanced diet-
induced AP proliferation. This dietary fat screen also provided an effective tool to 
ii 
 
investigate how expression of the adipokines, adiponectin and leptin, related to 
mechanisms of adipose expansion. Interestingly, VWAT expression of leptin 
correlated with several measures of adipocyte formation, contrasting with its 
typical association with hypertrophy. Finally, while studies using a lard-based 
HFD found increased expression of inflammatory and fibrotic markers with 
obesity, this screen also identified several diets that induce obesity but do not 
result in increased expression of these markers. This work identifies a novel 
mechanism to regulate diet-induced AP proliferation and highlights the need to 
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Chapter 1: Introduction 
Obesity, defined as the expansion of white adipose tissue (WAT), is 
becoming more prevalent, with 39% of the global population classified as 
overweight or obese in 20151. The association of obesity with a variety of 
comorbidities, including diabetes, cardiovascular disease2,3, stroke4, and cancer5, 
makes this trend particularly troubling. There are many hypotheses for what has 
driven this increase in obesity, including decreased physical activity, increased 
availability of food, and increased popularity of processed food6,7. Given this 
concerning trend, understanding mechanisms of adipose expansion and adipose 
homeostasis are vital to understanding and preventing human pathologies.  
In contrast to brown adipose tissue which functions in thermogenic regulation, 
WAT functions as an energy reservoir, storing energy-dense lipids until times of 
hunger or need. In times of caloric excess or deficit, the WAT may grow or shrink 
to provide or store triacylglycerides as needed. Regulation of these processes 
may be controlled by secreted hormones such as insulin, which inhibits lipolysis 
and promotes lipogenesis8, or through neuronal signaling which also controls 
lipolysis9. Adipose and its size are therefore at the center of energy balance, 
regulating calories stored and calories burned.  
In addition to its functions in energy storage and dispersal, WAT is also an 
endocrine organ, capable of secreting many factors and even producing some 
hormones that are specific to the adipose tissue, known as adipokines. 
Adiponectin and leptin are the classic adipokines. Adiponectin exerts a variety of 
functions, such as promoting insulin sensitivity10 and reducing inflammation11.  In 
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contrast, leptin is highly involved in energy balance, signaling satiety when 
secreted at high levels, decreasing in response to fasting, and promoting energy 
expenditure in lean subjects12–14. A leptin mutation is even the basis for one of 
the most commonly used mouse model of obesity; the ob/ob mouse exhibits 
dramatically increased food intake, resulting in a highly obese mouse that will 
lose weight dramatically upon the administration of leptin15,16.  
Adipose tissue is organized into distinct depots, with the inguinal 
subcutaneous (SWAT) and perigonadal visceral (VWAT) adipose being the most 
commonly studied in mice. These depots have many functional differences such 
as rates of lipolysis17, gene expression18, and adipogenic response to a high-fat 
diet (HFD)19. Preferential expansion of these two depots has been linked to 
differing disease outcomes. VWAT expansion is associated with increased 
likelihood of cardiovascular disease20, inflammation21, reduced angiogenic 
potential22, and diabetes risk23. In contrast, further work is needed to establish 
the role of SWAT in metabolic disease. While SWAT has been shown to be 
weakly correlated to diabetic and cardiovascular risk compared to VWAT24, other 
studies have linked this depot to a decreased risk of insulin resistance25,26. 
Alternatively, rather than quantify depot size, waist-to-hip ratio is a common 
method that is easy to measure and takes into account both SWAT and VWAT 
depots. A higher waist-to-hip ratio has been used as a risk factor for 
cardiovascular disease and mortality27. Given the different outcomes of 
expanding adipose in these depots, further work is needed to elucidate how 
expansion of these depots is regulated. 
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Mechanisms of adipose expansion 
In addition to location, adipose expansion must also be considered by its 
cellular mechanisms. Adipose tissue can grow via an increase in adipocyte 
number (hyperplasia) or an increase in adipocyte size (hypertrophy)28,29. 
Adipocyte hypertrophy is driven by the expansion of a single lipid droplet which 
can measure up to 100 µm in diameter and comprises most of the adipocyte 
volume30. A major mechanism of lipid droplet expansion is the uptake of lipids, 
primarily by the fatty acid (FA) scavenger, CD3631, or the insulin-sensitive FA 
transporter, FATP132. A second mechanism of lipid accumulation is the 
conversion of glucose to lipid via lipogenesis. This process of expansion must be 
balanced by lipolysis and the utilization of lipids for energy throughout the body. If 
the balance between lipid accumulation and usage is disrupted, the adipocyte 
may swell dramatically, potentially resulting in a thousand fold increase in volume 
and contributing to expansion of the WAT33.  
During prolonged caloric excess, hypertrophy may affect the homeostasis and 
function of the adipose tissue itself. Monteiro et al. used computational modeling 
to demonstrate that a large adipocyte may experience more physical stress and 
will be more likely to rupture with deleterious consequences34. Jo et al. also use a 
combination of modeling and observational studies to determine that larger 
adipocytes were more susceptible to death after prolonged HFD consumption35. 
Adipocyte death results in crown-like structures, a distinctive formation of 
macrophages around a dead adipocyte to clear lipid and debris. These 
macrophages tend to express a pro-inflammatory cytokine profile36, linking 
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adipocyte size and death to tissue inflammation. This adipose inflammation has 
linked adipocyte hypertrophy to a variety of systemic metabolic consequences, 
such as insulin resistance33,37,38, increased VLDL cholesterol39, and hepatic 
steatosis40.  
In addition to inflammation, adipose hypertrophy is associated with hypoxia, 
as oxygen can diffuse 100-200 μm into tissue41, less than the diameter of the 
largest adipocytes33. This hypoxia can then progress to adipose tissue fibrosis, 
mediated by chronic activation of Hypoxia-inducible factor 1α and the secretion of 
collagens by APs and fibroblasts42,43. Supporting this observation of progression 
to fibrosis, gene expression analysis of obese SWAT in humans has identified 
significant upregulation of fibrotic gene networks compared to lean, post-bariatric 
surgery WAT44. However, whether this fibrotic response is detrimental or 
protective is still being understood. While several studies have indicated that 
fibrosis may limit adipocyte size, releasing this check upon hypertrophy often 
results in decreased inflammation and improved metabolic health45,46. These 
data counter the hypothesis that hypertrophy inevitably leads to adipocyte 
rupture and macrophage infiltration, indicating that regulation of adipose 
homeostasis is a complex process and further understanding is needed.  
Finally, in addition to inflammation and fibrosis, adipocyte hypertrophy is 
linked to changes in adipokine production. Adipocyte size and obesity have been 
observed to correlate negatively to plasma adiponectin concentrations47,48. Leptin 
is positively correlated to adipocyte size which has been linked to its role in 
signaling fullness to the organism49,50. Many of these studies examine human 
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WAT small sample sizes or quantify adipokine production in vitro. While 
important, these findings should be supplemented with other studies using larger 
sample sizes and quantifying adiponectin and leptin in vivo.  
In contrast to adipocyte hypertrophy, which may quickly fluctuate in response 
to fasting and refeeding conditions51,52, adipose hyperplasia is an enduring 
change, due to the multi-year lifespan of an adipocyte53. Because adipocytes are 
post-mitotic, an increase in adipocyte hyperplasia occurs by the proliferation and 
differentiation of adipocyte precursors (APs). APs have been historically studied 
using the immortalized pre-adipose cell line called 3T3-L1 in vitro, which 
accumulates lipid when treated with an adipogenic cocktail, commonly including 
insulin, dexamethasone, and methylisobutylxanthine 54,55,56. 3T3-L1s cells have 
proven instrumental to understanding molecular pathways of adipogenesis. For 
example, 3T3-L1 cells were employed to identify Pparγ2 which is now known as 
the “master regulator” of adipogenesis57. 3T3-L1 cells were also instrumental in 
identifying many other crucial transcription factors regulating adipogenesis, such 
as Klf458, Krox2059, and Cebpα, Cebpβ, and Cebpδ60.  
However, despite the ease of culturing and differentiating 3T3-L1 cells, 
studying primary APs and in vivo models are still crucial to understanding of 
adipogenesis. The adipose tissue microenvironment contains a rich variety of cell 
types including mature adipocytes, neurons, endothelial cells, and immune cells 
all of which impact adipocyte function and formation. For example, macrophages 
have been shown to enhance adipogenesis in a 3D cell culture environment61. 
Additionally, blocking adipocyte formation in AP implants not only inhibits 
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angiogenesis, but using antibodies to block angiogenesis also inhibits 
adipogenesis, indicating dual regulation of these processes62. Finally, in addition 
to inter-cell crosstalk in vivo, because 3T3-L1 cells are derived from a clone54, 
they will fail to capture the array of AP subtypes present in adipose tissue63. 
Therefore, in vivo studies remain important to understanding adipose tissue 
regulation and growth.  
In 2008, Rodeheffer et al. identified a series of cell markers which defined the 
in vivo AP population64. The identity of these APs has been verified by their 
ability to differentiate in vitro and to reconstitute a functional fat pad in a 
lipodystrophic mouse, resulting in normalization of its blood glucose. Using flow 
cytometry, these APs are defined as CD45-; CD31-; CD29+; CD34+; Sca1+, with 
CD24 expression differentiating between subpopulations varying in commitment 
to the adipocyte lineage65. 
RNA-seq has become a valuable tool to identify alternative markers for APs 
and to identify subpopulations with varying functions. For example, Merrick et al. 
identified a DPP4+ population which progresses to the more committed ICAM1+ 
and CD142+ cells66. RNA-seq was also used to identify a population defined by 
expression of LY6C and PDGFRβ, known as fibro-inflammatory progenitors, or 
FIPs67. FIPs are non-adipogenic and inhibit the adipogenesis of other AP 
subpopulations. The existence of a non-adipogenic subpopulation of APs is 
further supported by Marcelin et al. who identified CD9 as a marker of a highly 
proliferative population of APs that promote fibrosis rather than adipogenesis68. 
Finally, Schwalie et al. used RNA-seq to identify the Areg population, a CD142+ 
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subpopulation of APs which inhibits adipogenesis in a paracrine mechanism69. 
These subpopulations indicate that APs are a diverse cell type with varying 
functions. Further work will be needed to ascertain the role of these 
subpopulations in WAT homeostasis.  
AP function also depends on adipose depot and microenvironment. For 
example, APs isolated from SWAT have greater adipogenic capacity in vitro than 
do APs isolated from VWAT70. In addition, SWAT and VWAT APs differ in their 
proliferative response to HFD. In male mice, VWAT APs undergo a transient 
burst of proliferation at the onset of HFD feeding which then subsides to baseline 
levels over the course of a week. Eight weeks later, this proliferative burst 
contributes to the formation of new adipocytes. In contrast, SWAT APs in males 
do not proliferate in response to HFD and do not result in hyperplasia19. This 
depot specificity is not found in female mice which exhibit an adipogenic 
response to HFD in both SWAT and VWAT71; however, male mice will primarily 
be used in the studies presented here. Diet-induced hyperplasia was determined 
to be dependent on Akt2-signaling, in a mechanism that is specific to obesity and 
HFD consumption and distinct from the adipose tissue establishment during 
development. These findings illustrate the importance of studying adipose 
hyperplasia in vivo within the appropriate context. These findings also illustrate 
the need to identify the adipogenic stimulus in HFD consumption which this work 





Fatty acid signaling and receptors 
When HFD is ingested, the lipids are packaged into chylomicrons for 
transport to the various tissues. In adipose tissue, membrane proteins facilitate 
the uptake of TGs into the tissue. For example, FATP1 is translocated to the 
plasma membrane by insulin, where it increases lipid uptake from the plasma32. 
In addition to FATP1, CD36 is another lipid transporter, with fatty acid uptake 
decreasing by 60-70% in CD30-ko mice72.  
In addition to storing dietary lipids, adipocytes and APs respond to them as 
signaling ligands. Dietary fats have been identified as a primary driver of 
adiposity, making them a potential candidate for AP activation and proliferation73. 
Fatty acids and other lipid-derived compounds known as lipokines are important 
modifiers of metabolic health, able to improve insulin signaling and 
hepatosteatosis74. Furthermore, fatty acids have also been shown to affect DNA 
methylation and adipokine secretion in adipocytes75,76. Given the association with 
obesity and HFD, additional work is needed to understanding how dietary fatty 
acids impact adipose expansion and overall health.  
The signaling functions of fatty acids in adipose tissue has spurred interest in 
their mechanisms. Fatty acids may signal via the Free Fatty Acid Receptor 
(FFAR) family, a group of G-protein coupled receptors which are categorized by 
the length of fatty acid to which they bind. This work will discuss Gpr120 (also 
known as FFAR4) and Gpr40 (also known as FFAR1) which bind to medium- and 
long-chain fatty acids77,78. Gpr40 is primarily expressed in the pancreas and 
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intestines79 and is known to mediate the effects of fatty acids on glucose-
stimulated insulin secretion, although whether it is harmful or beneficial has been 
controversial80. Nagasumi et al. overexpressed Gpr40 in murine pancreatic beta 
cells and determined that overexpression improved glucose tolerance and 
glucose stimulated insulin secretion in diet-induced obese mice81. However, 
Steneberg et al. found that Gpr40-/- mice were protected from obesity-associated 
glucose intolerance and insulin resistance and that overexpressing Gpr40 under 
the pancreatic promoter PDX1 increased hepatic steatosis and decreased 
glucose tolerance and glucose-stimulated insulin secretion82. Alquier et al. have 
attempted to reconcile these opposing views by noting that the PDX1 promoter 
expression is not restricted to the pancreas and is also expressed in the 
hippocampus. They also note that Steneberg et al.’s transgenic line may have 
suffered from developmental effects, as islet morphology appeared to be 
affected80. They suggest that evidence points toward Gpr40 signaling as 
beneficial for metabolic health. 
Unlike Gpr40, Gpr120 is known to be expressed in white adipose tissue. 
Furthermore, APs with reduced expression of Gpr120 have decreased 
adipogenic potential, with less lipid accumulation and decreased expression of 
the adipogenic genes Pparγ-2 and aP283. Hilgendorf et al. supported the 
importance of Gpr120 in adipogenesis, observing that Gpr120 are localized on 
AP cilia84. Although Gpr120-/- mice consuming a long-term HFD accumulate more 
adipose compared to their wild-type (WT) counterparts, embryonic fibroblasts 
derived from this mouse model have reduced adipogenic potential in vitro. 
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Adipocytes of these knockout obese mice are larger than WT, suggesting that 
they grow preferentially by hypertrophy rather than hyperplasia in response to 
diet85.  
In addition to its effects on adipogenesis, Gpr120 has been studied for its 
effects on inflammation and insulin resistance. Oh et al. observed that 
pharmacological activation of Gpr120 reduced inflammatory gene expression in 
an LPS-treated macrophage cell line, an effect that was inhibited when Gpr120 
was knocked down. In addition, while supplementing a HFD with omega-3 fatty 
acids improved insulin sensitivity, omega-3 fatty acids had no effect on insulin 
sensitivity in Gpr120-/- mice86.  
Another signaling receptor capable of responding to fatty acids is the liver X 
receptor (LXR)87. This is a nuclear hormone receptor with two isoforms, α and β. 
While LXRβ is expressed in most tissues, LXRα is expressed in tissues with high 
lipid metabolism, such as brown and white adipose tissue, intestine, kidney, and 
liver88. Published work on the role of LXRα in adipogenesis is contradictory. Seo 
et al. demonstrated increased adipogenesis in 3T3-L1 cells when treated with the 
LXRα activator, T0901317. Furthermore, they identified LXR binding sites in the 
promoter region of the adipogenic “master regulator” Pparγ. In contrast, 
Hummasti et al. did not observe any effects on 3T3-L1 differentiation when 
treated with another LXRα agonist, GW396589. This difference in results could be 
due to these agonists having different efficacies, with GW3965 being a weaker 
agonist in some cell types90.  
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 While most published work has focused on LXR signaling via its ligand 
binding mechanism, LXRα modulation is complex and can be regulated by its 
posttranslational modifications. Torra et al demonstrated that LXRα activity 
differed if it was activated via ligand binding or via dephosphorylation, with the 
modulator T0901317 activating both these mechanisms91. A later study used a 
mouse model containing a point mutation to induce a serine-to-alanine 
conversion at residue 196 in LXRα, eliminating the phosphorylation site in a 
macrophage cell line. This mutation resulted in a shift toward expression of 
proliferative genes in murine bone-derived macrophages. This shift in gene 
expression was determined to be independent of ligand binding by the LXRα 
agonist GW396592.  
 This work will elucidate mechanisms of adipogenesis, including 
investigating whether modulation of Gpr120, Gpr40, and/or LXRα plays a role in 
AP activation by diet. This work also leverages an isocaloric HFD screen with 
various fat sources, ultimately leading to the identification of a novel mechanism 
of AP proliferation, the characterization of the effects of dietary fat type on WAT 
gene expression and function, and greater context when considering WAT 
inflammation and fibrosis during obesity. This work aims to further our 
understanding of how dietary fats impact obesity while providing a quantitative 




Chapter 2: Dietary oleic acid induces AP proliferation via down-regulation 
and dephosphorylation of LXRα 
Results  
Effects of dietary fats on adipose hypertrophy and hyerplasia 
Jeffery et al. determined that adipose hyperplasia induced by HFD is a 
distinct process from hyperplasia to establish the WAT during development. 
However, the mechanism of diet-induced obesity remained unknown. To 
determine whether diet activation of APs is due solely to increased caloric intake, 
AP proliferation was quantified in mice pair-fed HFD to calorically matched mice 




Figure 1: Dietary fat source determines whether VWAT expands primarily via 
hypertrophy or hyperplasia. A) VWAT AP proliferation in mice fed SD or pair-fed HFD 
mice for 7 days. (n=5; unpaired t-test; experiment conducted by Christopher Church) B) 
AP proliferation in SWAT and VWAT normalized to the SD-fed VWAT proliferation. Mice 
were fed the indicated HFD for 7 days. (n=5-2; experiment conducted by Jennifer 
Kaplan) C) VWAT weights of mice which consumed the indicated HFD for 12 weeks 
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(n=4-5; measured by Jennifer Kaplan) D) Quantification of newly formed adipocytes from 
AdiCre-ER/mTmG mice. Mice were injected with tamoxifen then given indicated HFD for 
8 weeks. (n=3-18) E) Quantification of VWAT BrdU-labeled adipocyte nuclei. Mice were 
given indicated HFD with BrdU water for one week. BrdU water was then removed, and 
mice continued to consume indicated diet for a total of 12 weeks. (n=4-5). F) Mean 
VWAT adipocyte volume from mice which consumed the indicated HFD for 12 weeks. 
(n=4-5). Correlations between VWAT mass and G) average VWAT adipocyte diameter 
for each diet and H) average rate of adipocyte formation for each diet. (Significance 
calculated by one-way ANOVA multiple comparisons to SD or Spearman correlation) 
 
 
Although both sets of mice consumed the same number of calories, VWAT APs 
of HFD-fed mice had increased proliferation compared to APs of SD-fed mice 
(Figure 1A). These results indicate that AP activation by diet is not due solely to 
increased caloric intake, suggesting that composition of the diet itself drives AP 
proliferation. 
Increased dietary fat has been found to be more strongly associated with 
obesity compared to dietary carbohydrate and protein content93. To determine if 
dietary fat sources impact adipogenesis, we designed a series of identical, 
isocaloric 45% fat diets with varying fat sources. Mice were fed these diets for 
one week along with drinking water containing BrdU to quantify AP proliferation. 
After one week, VWAT APs demonstrated a highly varied response to the HFDs, 
with some diets such as Fish and Palm inducing no significant change in AP 
proliferation while Soybean and Peanut resulted in an increased proliferation 
(Figure 1B). SWAT AP proliferation was not significantly increased compared to 
SD. These data indicate that dietary fat source and composition are highly 
relevant to AP activation and proliferation. 
I next wanted to characterize the effects of these dietary fats on WAT 
expansion. WT mice that consumed the diets for 12 weeks demonstrated 
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variations in VWAT mass, with most diets increasing VWAT mass to varying 
degrees while other diets such as High Oleic (HO) Sunflower and HO Safflower 
did not increase VWAT compared to SD (Figure 1C). To determine whether diets 
that induced AP proliferation also resulted in increased adipocyte formation, diets 
were fed to the AdiponectinCre-ER/mTmG (AdiCre-ER/mTmG) mouse model for 
8 weeks to quantify adipogenesis as presented preivously94. In brief, this model 
utilizes an inducible Cre response element regulated by the adiponectin promoter 
so that upon induction, adipocytes transition from expressing a red fluorescent 
reporter to a green one. When mice are fed the indicated HFD, any adipocytes 
that form after induction will be red, allowing for the quantification of in vivo 
adipogenesis. In addition to increased AP proliferation, the Lard, Olive, and 
Soybean diets resulted in increased adipocyte formation compared to SD (Figure 
1D). However, HO Sunflower, HO Safflower, and Peanut diets which resulted in 
the most extreme increase in AP proliferation, resulted in lower rates of 
adipogenesis than expected and were not significantly increased. As an 
alternative measure of adipogenesis, I performed a BrdU pulse-chase to quantify 
BrdU-labeled adipocytes formed from diet-activated APs. In brief, mice were 
given the HFD and BrdU drinking water for one week. The BrdU was then 
removed, and the mice continued to consume the diet for 11 more weeks, 
allowing any activated APs to differentiate and form mature adipocytes. In this 
case, none of the diets resulted in a significant increase above SD within the 
context of the diet series (Figure 1E). However, these data appeared to mimic 
trends from the AdiCre-ER/mTmG mice with Lard, Olive, and Soybean having 
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more BrdU-labeled nuclei and HO Sunflower, HO Safflower, and Peanut having 
fewer labeled nuclei. Therefore, in addition to driving different rates of AP 
proliferation, dietary fat source affects adipocyte formation as well.  
Adipocyte size was quantified by staining fixed sections of adipose tissue 
with Masson’s trichrome stain and systemically imaging and quantifying 
adipocyte area. Interestingly, upon quantifying VWAT adipocyte volume, 
relatively few diets resulted in increased adipocyte size compared to SD. Yet 
diets with low adipocyte formation such as Butter and Palm diets had the most 
dramatic increases in adipocyte size. In contrast, diets resulting in greater 
adipocyte formation such as Olive and Soybean did not significantly increase 
adipocyte size (Figure 1F). These data suggest that dietary fat source may bias 
the tissue toward expanding primarily via hypertrophy or hyperplasia. 
In previously published work, comparing fat mass gain during 
consumption of a 60% lard HFD to SD consumption illustrated that both adipose 
hypertrophy and hyperplasia contribute to overall WAT mass71,95. However, we 
have used a series of HFDs, resulting in a variety of graded responses in fat 
mass gain. This approach allows us to separate and distinguish between these 
mechanisms to assess their effects on overall adipose mass. Quantifications of 
adipogenesis and adipocyte diameter from the dietary fat screen were correlated 
to each individual mouse’s VWAT mass. While adipocyte diameter had a strong 
and significant correlation to VWAT mass, adipogenesis demonstrated no such 
correlation, suggesting that in the more complex context of the dietary fat screen, 
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adipocyte size is a stronger driver of depot size than is adipogenesis (Figure 1G-
H).  
 
Figure 2: SWAT lacks an adipogenic response to HFDs and expands primarily via 
hypertrophy. A) SWAT mass after 12 weeks of diet consumption. (n=5; measured by 
Jennifer Kaplan) B) Quantification of newly formed SWAT adipocytes in AdiCre-
ER/mTmG mice after 8 weeks of HFD consumption. (n=3-18) C) Quantification of 
proportion of BrdU-labeled SWAT adipocyte nuclei in mice which ate diet for 12 weeks. 
(n=4-5) D) Mean SWAT adipocyte volume after 12 weeks of consuming indicated HFD. 
(n=4-5). Correlations between SWAT mass and E) SWAT adipocyte diameter and F) 
SWAT adipocyte formation in AdiCre-ER/mTmG mice. (Significance calculated by one-





In characterizing the WT SWAT mass after long-term consumption of 
indicated HFD, this tissue demonstrated a range of responses, with some strong 
increases in SWAT weight in diets such as Palm and Peanut and some moderate 
increases, such as during Palm consumption (Figure 2: SWAT lacks an 
adipogenic response to HFDs and expands primarily via hypertrophy. A) SWAT 
mass after 12 weeks of diet consumption. (n=5; measured by Jennifer Kaplan) B) 
Quantification of newly formed SWAT adipocytes in AdiCre-ER/mTmG mice after 8 
weeks of HFD consumption. (n=3-18) C) Quantification of proportion of BrdU-labeled 
SWAT adipocyte nuclei in mice which ate diet for 12 weeks. (n=4-5) D) Mean SWAT 
adipocyte volume after 12 weeks of consuming indicated HFD. (n=4-5). Correlations 
between SWAT mass and E) SWAT adipocyte diameter and F) SWAT adipocyte 
formation in AdiCre-ER/mTmG mice. (Significance calculated by one-way ANOVA 
multiple comparisons to SD or Spearman correlation)A). In contrast to VWAT, SWAT 
adipocyte formation in the AdiCre-ER/mTmG mice was not significantly 
increased compared to SD on the various HFDs (Figure 2B). Additionally, 
although there was variation in the proportion of BrdU-labeled SWAT adipocyte 
nuclei, none of the diets resulted in significantly greater adipogenesis compared 
to SD by this measure of hyperplasia (Figure 2C). Finally, like VWAT, 12 weeks 
of consuming the various HFDs resulted in varying SWAT adipocyte sizes with 
the Lard and Butter diets inducing significantly increased adipocyte size 
compared to SD (Figure 2D). Also, similarly to VWAT, SWAT mass was 
significantly correlated to adipocyte size rather than adipocyte formation (Figure 
2E-F). These data indicate that while there are depot-specific differences in how 
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dietary fats activate mechanisms of WAT expansion, hypertrophy remains the 
primary overall driver. 
Dietary oleic acid promotes AP proliferation and adipogenesis 
 
Figure 3: Dietary oleic acid drives AP proliferation and differentiation. A) 
Correlation between dietary oleic acid content and average fold increase in VWAT AP 
proliferation after one week of diet consumption. (Spearman correlation) B) Total plasma 
fatty acid concentration during first week of 60% lard HFD consumption. (n=5; unpaired 
t-test) C) Percentage change in plasma oleic acid concentration compared to Day 0 of 
HFD consumption. (n=5; unpaired t-test) D) Oleic acid content in VWAT during HFD 
feeding. (n=3, unpaired t-test E) Fat pad mass of mice which consumed SD with vehicle 
or SD supplemented with tri-oleate to 45% for 8 weeks (n=5; one-way ANOVA) F) AP 
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proliferation in SWAT and VWAT after one week of SD supplemented with vehicle or tri-
oleate. (n=5; one-way ANOVA) G) VWAT AP proliferation after 5 days of SD 
supplemented with purified fatty acids. (n=5; one-way ANOVA) H) AP proliferation after 
daily jugular infusions of oleic acid (20 mM) or vehicle (BSA) for 5 days. (n=5; one-way 
ANOVA) I) Lipid accumulation quantified by Oil Red O staining after 7 days of 
differentiation of primary APs. APs differentiated with insulin, insulin supplemented with 
indicated fatty acid (100 µM), or MDI. (n=3; one-way ANOVA compared to insulin) J) 
Lipid accumulation in primary human APs differentiated with MDI or MDI supplemented 
with oleic acid (100 µM) for 7 days. Human APs defined as CD45-; CD235-, CD90+, 




To determine mechanistically how dietary fats drive mechanisms of 
adipose expansion, lipidomic analysis was performed to determine the fatty acid 
composition of each diet. In correlating fatty acid composition to measures of 
hypertrophy and hyperplasia, oleic acid was found to be significantly and strongly 
correlated to AP proliferation (Figure 3A). This relationship contrasted with other 
fatty acids, such as 16:0, 18:0, and 18:2n-6, which are similar in structure and 
demonstrated no such correlation (data not shown). Previous studies have 
shown that AP proliferation peaks at Day 3 of HFD and subsides back to basal 
proliferation after the first week19. In quantifying plasma and adipose fatty acids 
after 3 or 7 days of a 60% lard-based HFD, total plasma fatty acids peaked at 
Day 3 and were decreased on Day 7 (Figure 3B). Plasma oleic acid mimicked 
the plasma fatty acid levels, increasing on Day 3 and decreasing on Day 7 
(Figure 3C).  In contrast, VWAT oleic acid increased steadily over the course of 
the week (Figure 3D). These results suggest that the decrease in plasma oleic 
acid and fatty acids is due to the absorption by WAT. These findings identify oleic 
acid as a potential nutritional signal driving in vivo AP proliferation. 
To determine whether oleic acid induces AP proliferation or is merely 
correlated with it, SD was supplemented with tri-oleate, a more stable form of 
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oleic acid. These diets were supplemented to 45% kcal fat, matching the custom 
diet series. Long-term consumption of this supplemented diet was sufficient to 
increase VWAT mass, while there was no effect on SWAT mass (Figure 3E). 
When mice were fed these diets for one week, the addition of tri-oleate was 
sufficient to induce a significant increase in AP proliferation in the VWAT, while 
there was no effect in the SWAT (Figure 3F). As another approach to this 
experiment, stearic acid (18:0), oleic acid (18:1), and linoleic acid (18:2) were 
directly supplemented into a SD. Of these fatty acids, only oleic acid induced AP 
proliferation in the VWAT, while stearic and linoleic acids were no difference than 
SD (Figure 3G). To determine whether oleic acid itself or a metabolite formed 
during absorption is responsible for inducing AP proliferation, mice were given 
jugular catheters to allow oleic acid to be administered directly into the blood 
stream. In this scenario, oleic acid was still sufficient to increase AP proliferation 
in VWAT (Figure 3H). These data show that dietary oleic acid is sufficient to 
induce AP proliferation in vivo.  
To further characterize the specificity of oleic acid in driving adipose 
hyperplasia, primary APs were harvested and cultured in vitro. The cells were 
then differentiated using either insulin, an adipogenic cocktail of insulin, 
dexamethasone, and 3-isobutyl-1-methylxanthine (MDI), or insulin supplemented 
with a screen of fatty acids. Of the fatty acid screen, only oleic acid (C18:1) and 
palmitoleic acid (C16:1) resulted in significantly more lipid accumulation (Figure 
3I). We also observed from our lipidomic data that the concentration of fatty acid 
used was physiologically relevant for oleic acid but was hyper-physiologic for 
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palmitoleic acid, suggesting that oleic acid remains a highly specific driver of 
adipogenesis. Finally, to determine whether oleic acid also increased lipid 
accumulation in human APs, we isolated primary APs from human adipose 
samples and differentiated them in the presence of oleic acid. Oleic acid 
significantly increased lipid accumulation (Figure 3J), suggesting this effect is not 
restricted to mice. These data show that oleic acid is capable of inducing 




Figure 4: OA increases adipogenesis by inducing Akt2 activation and lipogenesis. 
A) Lipid accumulation in primary APs sorted from WT or Akt2-/- mice differentiated with 
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insulin, MDI, or insulin supplemented with oleic acid (18:1; 100 µM) for 7 days. (n=3; 
one-way ANOVA) B) Immunoblot and quantification of Akt2 phosphorylation at Serine 
473 (S473) in primary APs after 3 hours of differentiation with insulin or insulin 
supplemented with oleic acid (18:1; 100 µM). (unpaired t-test) Gene expression of C) 
Pparγ, D) Cebpα, E) adiponectin, F) leptin, G) Fabp4, and H) perilipin in primary WT or 
Akt2-/- APs after 12 hours of differentiation with insulin or insulin supplemented with oleic 
acid (n=3; one-way ANOVA) I) Lipid accumulation in primary APs after 24 hours of 
differentiation with insulin, or insulin and oleic acid (OA; 100µM) with glucose uptake 
inhibitor or fatty acid synthase inhibitor. (± 25 mM glucose as indicated; n=3; unpaired t-
test) (All experiments performed by Christopher Church) 
 
 
Jeffery et al. found that Akt2 signaling is required for diet-induced 
adipogenesis yet is not required for hyperplasia during adipose establishment 
and development. To determine whether the ability of oleic acid to induce AP 
differentiation is dependent on Akt2, lipid accumulation was quantified in Akt2-/- 
APs. While oleic acid significantly increased lipid accumulation in the WT cells, 
this increase was ablated in the Akt2-/- cells (Figure 4A). To quantify Akt2 
activation during oleic acid treatment, phosphorylation of residue S473 was 
quantified. After 3 hours of differentiation, oleic acid supplementation resulted in 
significantly more Akt2 activation than insulin alone (Figure 4B). In addition to 
lipid filling, Akt2 is also required for the characteristic changes in gene expression 
that accompany adipogenesis. While WT APs increased expression of Pparγ, 
Cebpα, adipongectin, leptin, Fabp4, and perilipin in response to oleic acid, Atk2-/- 
APs failed to increase expression of these genes during differentiation (Figure 
4C-H). These data indicate that oleic acid acts in a signaling mechanism to 
activate Akt2 and suggests that oleic acid is a dietary ligand that promotes 
adipogenesis. 




Figure 5: Oleic acid decreases LXRα activity and phosphorylation. A) Heat map 
showing pathways which are up- or downregulated in sorted APs in response to 3 days of 
60% lard HFD consumption (n=3-5). VWAT expression of B) LXRα and C) Srebp-1c 
after 3 days of SD or HFD consumption. (n=5) D) LXR activity quantified by a luciferase 
reporter assay in 3T3-L1s after 24 hours treatment with MDI, MDI with oleic acid (OA; 
100 µM), or MDI with T0901317 (5 µM). (n=6) E) Dephosphorylation of LXRα is 
associated with upregulation of genes involved in proliferation. F) Western blot and 
quantification of p-LXRα in primary APs differentiated for 24 hours with insulin or insulin 
supplemented with oleic acid (OA; 100 µM), linoleic acid (LA; 100 µM), or T0901317 (5 





To identify a mechanistic pathway for how dietary oleic acid induces AP 
proliferation, I used our understanding of sex-dependent differences in WAT 
patterning. While male mice undergo diet-induced adipogenesis in the VWAT96, 
HFD induces adipogenesis in the SWAT and VWAT of female mice (Appendix 
Figure 18). I used an RNA-seq dataset collected from the SWAT and VWAT APs 
of male and female mice fed either SD or 60% lard HFD for 3 days, the time of 
maximal diet-induced AP proliferation96. I analyzed this dataset for pathways 
modulated by HFD that were consistent between the adipogenic depots—male 
VWAT and female SWAT and VWAT—and lacking in the nonadipogenic depot—
male SWAT. Downregulation of the LXR/RXR pathway was identified to be a 
strong hit fulfilling these criteria (Figure 5A). Of the LXR isoforms, LXRα was of 
particularly interest given its role in activating genes involved in lipogenesis and 
cholesterol transport97. LXRα is also known to be involved in oleic acid signaling, 
modulating oleic acid-induced hepatic lipogenesis98, and protecting against oleic 
acid-induced pulmonary inflammation99.  
To verify the results of the RNA-seq pathway analysis, APs were sorted 
from SWAT and VWAT of male mice fed either SD or 60% HFD for 3 days. Gene 
expression of LXRα and other genes downstream of LXRα signaling was then 
quantified. Interestingly, there was no change in expression of LXRα itself (Figure 
5B). However, expression of Srebp-1c, a gene regulated by LXRα signaling was 
decreased in the HFD SWAT and trending toward decreased expression in the 
VWAT (Figure 5C). These data suggest that while LXRα expression was not 
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affected, at least one of its downstream signaling pathways was downregulated, 
consistent with the RNA-seq dataset.  
To determine whether LXRα activity was being modulated specifically by 
oleic acid, 3T3-L1s were transfected with a luciferase reporter to quantify LXR 
activity. Cells were also treated with the LXRα modulator T0901317 as a positive 
control. While the T0901317 resulted in a strong increase in LXR activity, 
supplementation of oleic acid in the adipogenic cocktail significantly decreased 
LXR activity relative to MDI alone (Figure 5D). As LXRα expression was not 
affected by short-term HFD consumption, we considered posttranslational 
modifications as an alternative mechanism of regulation. The modulator 
T0901317 has been shown to increase LXRα phosphorylation91. Furthermore, 
dephosphorylation of LXRα  has been found to promote expression of 
proliferative genes in bone-derived macrophages (Figure 5E)92. The mechanisms 
of this signaling are still being understood. To determine whether oleic acid 
affects LXRα phosphorylation, primary APs were cultured and differentiated for 
24 hours. Treatment with oleic acid slightly decreased LXRα phosphorylation, 
while treatment with linoleic acid and T0901317 resulted in increased LXRα 
phosphorylation (Figure 5F). While this experiment will be repeated in the near 
future, these data suggest that oleic acid decreases LXRα activity and its 





Figure 6: LXRα phosphorylation is inhibitory to VWAT diet-induced AP 
proliferation. A) AP proliferation in mice given 60% Lard HFD and daily injections of 
vehicle (MCT) or T0901317 (50 mg/kg) for 3 days with BrdU drinking water. (n=5) B) 
Quantification of the percentage of APs (Sca1+ cell) which are p-LXRα+. (n=4-5) 
Quantification of C) VWAT and D) SWAT AP proliferation measured by Ki67 expression 
in WT (C5Bl/6J) or S196A LXRα mice after 3 days of SD or HFD consumption. (n=5-6) 
(Significance measured by unpaired t-test) 
 
 
To quantify how modulation of LXRα signaling affects AP proliferation in 
vivo, mice were treated with T0901317 along with 3 days of 60% lard HFD 
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feeding. While T0901317 did not affect AP proliferation relative to vehicle in the 
SWAT over this time course, it led to a decrease in VWAT AP proliferation 
(Figure 6A). This depot specificity suggests that LXRα activation prevents diet-
induced AP proliferation.  
To determine how LXRα phosphorylation is affected by short-term HFD 
consumption in vivo, immunohistochemistry was used to stain VWAT with Sca1 
to mark APs and p- LXRα. The proportion of APs with phosphorylated LXRα was 
then quantified in mice fed SD or HFD for 3 days. Short-term HFD consumption 
resulted in decreased APs with phosphorylated LXRα (Figure 6B). Finally, to 
determine whether decreased LXRα phosphorylation is involved in diet-induced 
AP proliferation, mice with a serine-to-alanine mutation at an LXRα 
phosphorylation site (S196A) were obtained. These mice were fed SD or 60% 
lard HFD for 3 days. VWAT AP proliferation in the S196A mice was not affected 
when the mice consumed SD. However, when the mice were given HFD, VWAT 
AP proliferation in the S196A mice was strongly induced and was significantly 
greater than AP proliferation in the HFD-fed WT mice (Figure 6C). This finding 
indicates that LXRα phosphorylation is inhibitory to diet-induced AP proliferation 
but does not affect basal VWAT proliferation. Interestingly, in the SWAT, while 
there was no diet-induced AP activation, proliferation in the SD- and HFD-fed 
S196 mice were significantly increased over the WT proliferation, suggesting that 
LXRα phosphorylation may be also be involved in inhibiting the proliferative 
response in SWAT (Figure 6D). These data show that LXRα phosphorylation 







Using a matched series of HFDs, we have shown that the type of dietary fat 
influences whether adipose expands primarily through hyperplastic or 
hypertrophic mechanisms, or both. This HFD screen identifies oleic acid as a 
dietary driver of AP proliferation that increases Akt2 phosphorylation and 
lipogenesis. Finally, I have also identified LXRα phosphorylation as an inhibitory 
mechanism of diet-induced AP proliferation. 
Many other studies have illustrated the significant role fatty acids play in 
regulating adipose phenotypes, such as inflammation 100, adiposity 101, and 
insulin signaling 102. However, we utilized a series of isocaloric HFDs that are 
identical except for the fat sources, allowing us to focus on the in vivo effects of 
dietary fats without being confounded by differing carbohydrates and proteins 
between the diets. Furthermore, the use of several HFDs, as opposed to 
comparing a low-fat diet to HFD, has yielded more graded responses, allowing 
the identification of trends that may otherwise be obscured by studying two 
extremes in fat content. For example, while we have previously shown that 
adipogenesis correlates with adipose depot weight when comparing SD to a 60% 
HFD 103, our approach allowed us to define a more nuanced context of many 
HFDs in which adipocyte size was found to be more tightly linked to depot 
weight. 
Using correlations between dietary fatty acid composition and measures of 
adipose expansion, oleic acid was identified as a dietary signal inducing AP 
activation and proliferation. The primary source of oleic acid in the human diet is 
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olive oil, which is a major component of the Mediterranean diet. In addition to its 
association to decreased cardiovascular disease and cancer risks 104,105, the 
Mediterranean diet has also been studied as a potential therapy for weight 
loss106,107. In other studies, it has been praised as a palatable, non-obesogenic 
diet, despite its high proportion of fat, primarily comprising of olive oil 108–110. 
Therefore, it is perhaps surprising that our findings identify oleic acid as a dietary 
driver of AP proliferation. However, Mediterranean diet is characterized by 
several other parameters, including high consumption of fruits, vegetables, 
legumes, and unrefined cereals and grains which can also have benefits on 
health 111. Additionally, although oleic acid is a major component of olive oil, extra 
virgin olive oil, a healthier variation of refined olive oil, also contains many other 
compounds such as polyphenols and vitamins. In particular, polyphenols have 
been identified as the potential drivers of the cardiovascular and inflammatory 
benefits of olive oil 112–114. Therefore, this identification of oleic acid as a dietary 
signal inducing AP activation is not necessarily inconsistent with the 
Mediterranean diet’s association with longevity.  
Furthermore, lipodystrophic models illustrate the dire consequences to 
metabolic health in the absence of adipose, indicating that some adipose tissue 
is necessary to store and manage lipids 115,116. This metabolic phenotype can 
even be reversed with the addition or reinstallation of white adipose tissue 64,117. 
The overflow model expands upon this idea, identifying adipose tissue expansion 
as a compensatory mechanism to sequester lipids away from ectopic storage 
such as in muscle and liver 118–120. Furthermore, the formation of many, small 
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adipocytes has been related to improved insulin sensitivity and metabolic health 
38,121. Adipogenesis is also a hypothesized mechanism behind thiazolidinediones, 
a class of Ppar-γ agonists that improve insulin resistance, but are associated with 
adipose gain through adipogenesis 122–124. Further work on mice consuming this 
HFD series will be able to reveal whether dietary oleic acid is associated with any 
metabolic pathologies. 
Our data finds that oleic acid promotes adipogenesis via Akt2 signaling 
and stimulation of lipogenesis. These data also make the novel discovery of 
LXRα phosphorylation as a regulatory mechanism to inhibit AP proliferation. 
Knockout of LXRα in adipose tissue has been published to result in substantially 
increased fat mass and larger adipocyte size125. Additionally, prolonged 
treatment of ob/ob mice with the LXRα agonist GW3965 resulted in redistribution 
of adipose tissue shifting from VWAT to SWAT but did not alter adipocyte size or 
number126. However, while these mouse models target expression of LXRα or 
activate it via ligand binding, our hypothesis addresses modulation of LXRα 
signaling via its dephosphorylation. The mechanism of LXRα activation, whether 
through ligand or posttranslational modification, regulates its downstream activity 
and signaling91,92. I observed high basal rates of LXRα phosphorylation in VWAT 
APs, consistent with the low basal rates of AP proliferation during SD 
consumption. Additionally, I observed increased VWAT AP proliferation during 
HFD consumption, but no effect on AP proliferation of SD-fed mice, suggesting 
that the S196A mutations affects diet-induced proliferation, rather than basal 
proliferation. These data identify a novel mechanism to regulate AP proliferation 
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in response to HFD. Further work should be done to determine whether LXRα 
phosphorylation also plays a role in AP differentiation or if it is solely involved in 
AP activation.  
Our HFD series has illustrated the significant influence dietary fats play in 
mechanisms of adipose expansion. We have also identified oleic acid as a 
dietary fatty acid capable of inducing AP proliferation and lipogenesis. Other fatty 
acids should be studied to determine whether they mediate the many other 
health disorders associated with obesity. I have identified LXRα phosphorylation 
as a novel regulator of AP activation. The ability of this HFD series to bias 
adipose tissue expansion toward hypertrophy or hyperplasia provides a tool to 
understand how these mechanisms relate to metabolic pathologies associated 




Chapter 3: Gpr120 and Gpr40 are not required for diet-induced AP 
proliferation 
Results  
Gpr120 and Gpr40 do not mediate diet-induced AP proliferation 
With the identification of dietary oleic acid as a driver of AP proliferation, I 
was motivated to consider potential receptors that could mediate oleic acid 
signaling, which led me to focus on Gpr120 and Gpr40. These receptors belong 
to the Free Fatty Acid Receptor family and are activated by medium- to long-
chain fatty acids77,127,128. While Gpr40 has primarily been studied for its role in 
insulin-stimulated glucose secretion in the pancreas129, Gpr120 is expressed in 
WAT, and has been shown to promote differentiation of 3T3-L1 cells83. However, 
in vivo work on the role of Gpr120 in adipogenesis has been limited. 
To determine the effects of Gpr120 and Gpr40 on adipose hyperplasia, we 
obtained whole-body Gpr120-knockout (Gpr120KO) and Gpr40-knockout 
(Gpr40KO) mice. To verify the knockout and ensure that knockout of one 
receptor did not result in a compensatory increase in expression of the other 
receptor, I quantified gene expression in these mice.  
 
Figure 7: Expression of Gpr40 and Gpr120 does not increase in the knockout of 
the other receptor. A) Expression of Gpr40 in sorted SWAT and VWAT APs from WT, 
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Gpr120KO, and Gpr40KO mice. (n=3) B) Expression of Gpr120 in sorted SWAT and 
VWAT APs from WT, Gpr120KO, and Gpr40KO mice. (n=3; two-way ANOVA) 
 
 
The Gpr40KO mice demonstrated highly efficient knockout of Gpr40 expression 
in both the SWAT and VWAT (Figure 7A). Expression of Gpr120 was also nearly 
eliminated in the Gpr120KO mice in both SWAT and VWAT (Figure 7B). 
Interestingly, Gpr40 expression was also decreased in the Gpr120KO VWAT. 
These data indicated that the knockout mouse models were highly efficient and 
did not result in compensatory overexpression of the opposite receptor. 
Previous work in the lab quantified proliferating APs in whole-body Gpr120 
or Gpr40 knockout mice. After 3 days of HFD consumption, while proliferation in 
VWAT of Gpr120KO APs was similar to that of WT mice, proliferation in VWAT 
Gpr40KO APs was decreased compared to WT mice. These data initially 




Figure 8: Gpr40 and Gpr120 are not required for diet-induced AP proliferation.  
VWAT AP proliferation in WT and Gpr40KO mice fed HFD for 7 days. (n=4-16) B) VWAT 
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AP proliferation in WT and Gpr120KO mice fed HFD for 7 days. (n=7-8) C) SWAT AP 
proliferation in WT and Gpr40KO mice fed HFD for 7 days. (n=4-16) D) SWAT AP 
proliferation in WT and Gpr120KO mice fed HFD for 7 days. (n=7-8) E) VWAT AP 
proliferation in Gpr40Het/Gpr120KO, Gpr40KO/Gpr120Het, or Gpr40KO/Gpr120KO 
mice fed HFD for 7 days (n=2-10) F) SWAT AP proliferation in Gpr40Het/Gpr120KO, 
Gpr40KO/Gpr120Het, or Gpr40KO/Gpr120KO mice fed HFD for 7 days. (n=2-10) G) 
VWAT AP proliferation in WT or Gpr40KO mice fed HFD for either 3 days or 6 days. 
(n=4-5) H) Proliferation of injected (Donor) or endogenous WT APs or Gpr40KO APs 
which were transplanted into the VWAT of WT mice which was then fed HFD for 7 days. 
(n=6) (Significance calculated by unpaired t-test) 
To repeat this result, I subjected Gpr120KO and Gpr40KO mice to our typical 
assay of one week of HFD19. In contrast to previous results, in the VWAT, both 
Gpr120KO and Gpr40KO mice exhibited increased AP proliferation when HFD-
fed compared to Chow-fed knockouts (Figure 8A-B). As expected for male mice, 
neither the Gpr40KO or Gpr120KO mice demonstrated diet-induced AP 
proliferation in the SWAT (Figure 8C-D). As these receptors bind to similar 
ligands, one hypothesis was that the two receptors may act redundantly. To 
address this idea, I bred mice that lacked both the Gpr120 and Gpr40 receptors. 
However, when these mice were fed a HFD for one week and compared to their 
heterozygous littermates, there was no still difference in VWAT AP proliferation 
(Figure 8E). Again, as expected, there was no difference in the SWAT AP 
proliferation in HFD-fed double-knockout mice compared to heterozygous 
littermates (Figure 8F). These data indicate that neither Gpr120 nor Gpr40 are 
required for diet-induced AP proliferation.  
Gpr40 mediates secretion of intestinal hormones, such as cholecystokinin 
which aids in digestion of fats and proteins130. This role in lipid digestion could 
impact the timing of fatty acid absorption and could contribute to the apparent 
discrepancies between previous data in which decreased AP proliferation in 
Gpr40KO mice was observed and my results that fail to detect any effect. To test 
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this hypothesis, I quantified AP proliferation during 0-3 days and 3-6 days of HFD 
consumption. There was no significant induction of AP proliferation during days 
0-3 of HFD, explaining how our initial, 3 day experiment identified Gpr40 deletion 
as inhibitory to AP proliferation. However, during 3-6 days, AP proliferation was 
strongly induced in the Gpr40KO mice, even compared to WT mice, suggesting 
that AP proliferation is not inhibited but merely delayed in these mutant mice 
(Figure 8G).  
To remove the effects of this delayed response, we sought to determine 
whether AP-intrinsic expression of Gpr40 impacted hyperplasia by performing 
cell transplants as detailed in Jeffery et al131. In brief, Gpr40KO mice were 
crossed to mTmG mice, causing all cells to express the red fluorescent protein 
Tomato in their membranes. APs were harvested from these mice and injected 
into the VWAT of B6 mice, whose cells lacked the Tomato expression. In 
comparing the proliferation of the endogenous, WT cells and the donated, 
Gpr40KO cells, there was no difference in proliferation between either of these 
cell types (Figure 8H). These data demonstrate that AP expression of Gpr40 is 
not required for a proliferative response to HFD.  
Gpr40 and Gpr120 do not affect adipose hypertrophy or hyperplasia 
While Figure 8 indicates that Gpr120 and Gpr40 were not required for a 
proliferative response to HFD, these receptors could nonetheless affect 
subsequent differentiation after the activation phase. To test this idea, I fed HFD 




Figure 9: Knockout of Gpr40 and Gpr120 does not affect adipocyte hyperplasia or 
hypertrophy. A) Body weights over time of WT or Gpr40KO mice fed SD or HFD for a 
total of 8 weeks. (n=5-6) B) Body weights over time of WT or Gpr120KO mice fed SD or 
HFD for a total of 8 weeks. (n=4-5; multiple t-test comparing Gpr40KO HFD to WT HFD) 
C) Mass of VWAT from WT or Gpr40KO mice. D) Mass of VWAT from WT or Gpr120KO 
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mice fed SD or HFD. E) Mass of SWAT from WT or Gpr40KO mice fed SD or HFD. F) 
Mass of SWAT from WT or Gpr40KO mice fed SD or HFD. G) Percentage of BrdU-
labeled adipocyte nuclei in VWAT of WT or Gpr40KO mice fed HFD for 8 weeks. H 
Percentage of BrdU-labeled adipocyte nuclei in VWAT of WT or Gpr120KO mice fed 
HFD for 8 weeks. I) Average adipocyte volume in VWAT of WT or Gpr40KO mice fed 
HFD for 8 weeks. J) Average adipocyte volume in VWAT of WT or Gpr120KO mice fed 
HFD for 8 weeks  
  
 
While the Gpr40KO mice were not heavier than the WT mice on both HFD 
and Chow (Figure 9A), the HFD-fed Gpr120KO mice were significantly heavier 
than the HFD-fed WT mice (Figure 9B). This difference becomes significant at 3 
weeks of HFD consumption which is earlier than the 8 weeks needed to for 
activated APs to differentiate. Interestingly, while the HFD-fed Gpr40KO mice 
consumed similar quantities of food to the HFD-fed WT mice (Figure 9C), the 
HFD-fed Gpr120KO mice consumed more calories during the initial period of diet 
consumption (Figure 9D). When quantifying depot weight, while the VWAT of the 
Gpr120KO and Gpr40KO mice were similar to WT mice (Figure 9E-F), the SWAT 
of the HFD-fed Gpr120KO mice was heavier than the SWAT of the WT mice 
(Figure 9E-H). The SWAT of the HFD-fed Gpr40KO mice was not statistically 
increased from the SWAT of the WT mice. This characterization of these 
knockout mice indicates that while there are slight differences in the Gpr120KO 
body weights and SWAT, there is no difference in the mass of the adipogenic 
depot, the VWAT, in either of these knockouts.  
To determine whether these receptors impact adipogenesis, I performed a 
BrdU pulse-chase as presented previously19. In brief, mice were given BrdU 
drinking water along with HFD for one week after which the BrdU was removed, 
and the mice continued to consume HFD for a total of 8 weeks. This assay 
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allows quantification of APs that were activated to differentiate by the HFD. After 
8 weeks of HFD, there was no difference in the proportions of BrdU-labeled 
adipocyte nuclei in either HFD-fed Gpr120KO or Gpr40KO mice compared to WT 
mice (Figure 9I-J). Finally, to determine whether knockout of Gpr120 or Gpr40 
impacted adipose hypertrophy, I quantified adipocyte volume from confocal 
microscopy images taken of stained tissue. There was no statistically significant 
difference between the volumes of VWAT adipocytes in WT and Gpr120KO or 
Gpr40KO mice (Figure 9K-L), indicating that. These data indicate that Gpr120 
and Gpr40 do not affect adipose hypertrophy or hyperplasia. 
 
Discussion 
Given the work identifying dietary oleic acid as a driver of AP proliferation, 
we sought to identify receptors that mediate this signaling. However, using a 
variety of assays, my studies clearly demonstrate that Gpr120 or Gpr40 do not 
exert strong influences on AP proliferation or differentiation.  
Previous works have suggested that knockout of Gpr120 reduces 
adipogenesis132, while treatment with small molecule Gpr120 agonists increase 
in vitro adipogenesis133,134. However, these studies have been in vitro, using 
either primary cells or the adipocyte precursor cell line 3T3-L1. In contrast, in 
using a whole-body knockout of Gpr120, there was no impact on in vivo AP 
proliferation or differentiation. Given that our mouse model was a whole-body 
knockout, perhaps a more targeted knockout only in APs would reiterate the 
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results observed in vitro. Nonetheless, our data demonstrate the need to verify in 
vitro findings in vivo.                                                                                                                     
Ichimura et al. identified that knockout of Gpr120 exacerbates diet-induced 
obesity, with Gpr120KO mice exhibiting increased fat mass and adipocyte area 
when consuming either SD or HFD132. While I also determined that HFD-fed 
Gpr120KO mice were heavier than their WT counterparts, I did not identify any 
impairment in adipocyte formation or size. However, obesity studies often last for 
longer than 8 weeks, and continuing to feed GPR120KO mice beyond the 8 
weeks could recapitulate a significant increase in adipocyte size, as published.  
Very little has been studied about the role of Gpr40 in adipogenesis as this 
receptor is not highly expressed in adipose tissue128. My data establishes that 
APs do indeed express low levels of Gpr40. However, knockout of Gpr40 did not 
affect AP proliferation, differentiation or body weight. This finding was consistent 
even when Gpr40KO APs were transplanted into WT mice, indicating that my 
findings are not due to whole-body knockout of the receptor. Therefore, while 
Gpr40 signaling impacts other facets of metabolism, it is less relevant for 
obesity135,136.  
My data has demonstrated that the FFARs Gpr120 and Gpr40 are not 
required for an adipogenic response to HFD. However, these receptors play vital 
roles in systemic metabolism, and Gpr120 expression is demonstrated to be 
important to regulation of obesity. Further work will be needed to determine if this 




Chapter 4: HFD screen impacts WAT gene expression and identifies 
relationships between WAT expansion mechanisms and adipose function 
Results 
Dietary fat screen identifies relationships between adipokine expression and 
mechanisms of adipose expansion 
 Mechanisms of adipose tissue expansion have been linked to varying 
outcomes for tissue function and systemic metabolic health, with hyperplasia 
being linked to a more metabolically healthy WAT and hypertrophy being linked 
to inflammation, fibrosis, and systemic insulin resistance137. I have demonstrated 
that dietary fat source is highly relevant in modulating expansion primarily via 
hypertrophy or hyperplasia. Furthermore, our HFDs induce varying responses in 
WAT gain, enabling us to study the effects of graded levels of obesity rather than 
comparing the extremes of lean or obese mice. These observations illustrate the 
potential of our 45% HFD screen as a tool to study how dietary fats affect 
adipose function and how these changes are related to mechanisms of adipose 
expansion.  
 To characterize how dietary fat source impacts expression of adipokines, 
qPCR was used to quantify gene expression of leptin and adiponectin in mice 




Figure 10: VWAT adiponectin expression correlates negatively with hypertrophy 
and dietary and plasma palmitic acid. A) VWAT expression of adiponectin from mice 
fed indicated HFD for 12 weeks. Normalized to expression of β-actin. (n=5-10; one-way 
ANOVA compared to SD). Correlations between average VWAT adiponectin expression 
for each diet and B) average VWAT adipocyte diameter, C) average VWAT hyperplasia 
quantified using the AdiCre-ER/mTmG mice, D) average VWAT AP proliferation during 
the first week of HFD consumption, E) dietary palmitic acid content of each HFD, F) 
average plasma concentration of nonesterified palmitic acid after 12 weeks of HFD 
consumption, and G) plasma concentration of total palmitic acid after 12 weeks of HFD 
consumption. (significance assessed using Spearman correlation) 
 
 
In the VWAT, while the Lard, Butter, and Palm diets significantly decreased 
adiponectin expression compared to SD, mice consuming the other diets 
displayed no change in expression compared to SD (Figure 10A). As adiponectin 
has been linked to adipocyte size47, it is perhaps expected that expression of 
46 
 
adiponectin and measures of adipose tissue expansion were correlated. 
Consistent with other publications47,48,50, VWAT adipocyte size was negatively 
correlated to VWAT adiponectin expression, while there was no such correlation 
between VWAT adiponectin expression and hyperplasia measures such as 
VWAT adipocyte formation and VWAT AP proliferation (Figure 10B-D). 
Interestingly, VWAT adiponectin expression was negatively correlated to palmitic 
acid content in the HFD, plasma palmitic acid in the form of non-esterified fatty 
acid, and total plasma palmitic acid in all forms (Figure 10E-G). These data 
indicate that dietary fat type impacts VWAT adiponectin expression, possibly via 
palmitic acid content of the diet. 
 
Figure 11: SWAT adiponectin expression does not correlate to measures of 
adipose expansion. A) SWAT expression of adiponectin from mice fed indicated HFD 
for 12 weeks. Normalized to β-actin expression (n=5-10; one-way ANOVA). Correlations 
between average SWAT adiponectin expression for each diet and B) average SWAT 
adipocyte diameter for each HFD, C) average SWAT hyperplasia quantified using the 
AdiCre-ER/mTmG mice, and D) average SWAT AP proliferation after HFD consumption 





In contrast to the VWAT, SWAT expression of adiponectin was only 
increased in mice that ate the Soybean diet (Figure 11A). Additionally, there were 
no correlations between SWAT adiponectin expression and SWAT adipocyte 
size, formation, or SWAT AP proliferation (Figure 11B-D), suggesting that there 
is a depot specificity in adiponectin’s relationship to adipocyte hypertrophy and 
that SWAT adiponectin expression may be regulated through other mechanisms.  
In addition to adiponectin, leptin expression was also quantified after 12 




Figure 12: VWAT expression of leptin is linked to hyperplasia, rather than 
hypertrophy. A) VWAT expression of leptin from mice fed indicated HFD for 12 weeks. 
Normalized to β-actin expression. (n=5; ** one-way ANOVA compared to SD; # unpaired 
t-test to SD) Correlations between average VWAT leptin expression for each diet and B) 
average VWAT adipocyte diameter after 12 weeks of diet consumption, C) average 
adipocyte formation quantified in AdiCre-ER/mTmG mice, and D) average percentage of 
BrdU-labeled VWAT adipocyte nuclei. Correlations between average plasma 
concentration of leptin after 12 weeks of HFD consumption and E) average VWAT 
adipocyte diameter, F) average VWAT adipocyte formation as quantified in AdiCre-
ER/mTmG mice, and G) average VWAT BrdU-labeled adipocyte nuclei. F) Correlation 
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between average VWAT leptin expression and average VWAT proliferative APs from 
each HFD. (Significance of correlations measured using Spearman correlation) G) 
VWAT leptin expression in WT or PdgfRα-Cre/Akt2fl/fl after consuming SD or HFD for 8 
weeks. Normalized to expression of β-actin. (n=2-5; unpaired t-test) H) Distribution of 




Mice that consumed Olive and Soybean diets had increased leptin expression 
compared to SD, although expression on the Lard diet would also be considered 
significant if this diet were compared directly to SD (Figure 12A). As Leptin 
expression has previously been linked to adipocyte size138,139, correlations were 
again performed between VWAT leptin expression and mechanisms of VWAT 
expansion. In assessing correlations to determine the relationship between leptin 
expression and hypertrophy and hyperplasia, VWAT leptin expression 
surprisingly bore no relationship to VWAT adipocyte size (Figure 12B). Instead, 
VWAT leptin expression correlated significantly with two measures of 
hyperplasia—VWAT adipocyte formation quantified from the AdiCre-ER/mTmG 
mouse model, and BrdU-labeled adipocyte nuclei (Figure 12C-D). To verify 
whether these relationships were limited to gene expression, correlations to 
quantification of plasma leptin were also analyzed. While there was no 
correlation between plasma leptin and VWAT adipocyte size, plasma leptin was 
significantly correlated to the proportion of BrdU-labeled adipocyte nuclei, while 
adipocyte formation approached, but did not achieve, significance (Figure 12E-
G). These findings show that leptin production did not correlate to hypertrophy 
and surprisingly correlated to measures of hyperplasia.   
 In examining the relationship between VWAT leptin expression and AP 
activation, 9 out of the 12 HFDs demonstrated a very strong correlation to VWAT 
50 
 
leptin expression (Figure 12H). However, the other three diets, HO Sunflower, 
HO Safflower, and Peanut, fall away from this trend. Interestingly, these three 
diets all have high rates of AP proliferation, yet lower rates of adipocyte formation 
(Figure 1D), highlighting the relationship to adipocyte formation.  
 After observing a correlation between leptin expression and adipocyte 
formation, I wanted to examine further whether adipocyte formation causes an 
increase in tissue-level leptin expression or whether this relationship is merely 
correlational. Akt2-/- mice lack an adipogenic response to HFD, yet have normal 
rates of adipocyte formation during WAT development96, making these mice an 
effective tool to study processes related to obesogenic hyperplasia. To target 
Akt2 knockout to APs, I used a PdgfRα-Cre/Akt2fl/fl mouse line which targets the 
APs to compare leptin expression. While HFD-fed WT mice had increased VWAT 
leptin expression compared to SD, HFD failed to increase leptin expression in the 
PdgfRα-Cre/Akt2fl/fl mice (Figure 12I). Furthermore, when quantifying adipocyte 
size in these mice, there was no difference in adipocyte hypertrophy in HFD-fed 
WT mice compared to HFD-fed PdgfRα-Cre/Akt2fl/fl mice, further demonstrating 
that leptin expression is not dependent on adipocyte size (Figure 12J). This 
experiment shows that increased leptin expression due to HFD consumption is 




Figure 13: SWAT leptin expression is not correlated to measures of adipose 
expansion. A) SWAT expression of leptin in mice which consumed indicated HFD for 12 
weeks. Data are normalized to β-actin. (n=5; one-way ANOVA) Correlations between 
average SWAT leptin expression after 12 weeks of indicated HFD consumption and B) 
average SWAT adipocyte diameter, C) average SWAT adipocyte formation measured in 
AdiCre-ER/mTmG mice, D) average SWAT AP proliferation during first week of HFD 
consumption.   
 
 
In contrast to VWAT, in the SWAT, many diets—Butter, Palm, Coconut, 
Soybean, and Peanut—resulted in increased leptin expression (Figure 13A). 
However, SWAT expression of leptin was not correlated to any measures of 
adipose expansion, including SWAT adipocyte diameter, SWAT adipocyte 
formation, or the percentage of BrdU-labeled SWAT adipocyte nuclei (Figure 
13B-D), showing that SWAT leptin expression is not related to any mechanisms 
of adipose expansion.  





Figure 14: HFD screen identifies correlation between Tnf-α and measures of 
hyperplasia. VWAT expression of A) Tnf-α, B) IL-6, and C) IL-1β from mice fed 
indicated HFD for 12 weeks. Gene expression is normalized to β-actin expression. (n=5, 
* one-way ANOVA multiple comparisons to SD, # unpaired t-test to SD) Correlations 
between average VWAT expression of Tnf-α for each diet and D) average VWAT 
adipocyte diameter for each diet, E) average percentage of BrdU-labled VWAT 
adipocyte nuclei, and F) average proliferation of VWAT APs after one week of HFD 
consumption. (Spearman correlation) 
 
 
 In addition to modulation of adipokine production, obesity is linked to 
measures of systemic and WAT-resident inflammation140,141 and adipose 
fibrosis44,142. Increased WAT expression of inflammatory and fibrotic genes is 
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linked to increased plasma insulin143 and decreased insulin sensitivity144,145. To 
quantify markers of inflammation, I selected Tnf-α, IL-6, and IL-1β due to their 
published increases in expression during obesity and their association to 
worsened metabolic health143,145–147. Interestingly, when quantifying Tnf-α 
expression in VWAT, the Fish and Palm diets resulted in increased Tnf-α 
expression (Figure 14A). For comparison, a 60% Lard diet, which is classically 
used in obesity studies148 was also used, which resulted in increased Tnf-α 
expression when compared directly to the Chow diet. Expression of IL-6 was also 
quantified, with only the 45% Lard diet resulted in increased VWAT IL-6 
expression (Figure 14B). Finally, VWAT IL-1β expression was quantified with 
Soybean diet resulting in increased expression (Figure 14C). Interestingly, both 
45% and 60% Lard HFDs resulted in significantly lower expression of IL-1β when 
compared directly to SD. These results demonstrate the importance of dietary fat 
type to WAT gene expression, with some diets increasing expression of these 
inflammatory genes and others having no effect. 
 In assessing how expression of inflammatory factors correlate to 
mechanisms of adipose expansion, VWAT expression of Tnf-α was negatively 
correlated to two measures of hyperplasia- proliferative APs and BrdU-labeled 
adipocyte nuclei (Figure 14D-E). In contrast, there was no correlation between 
Tnf-α expression and VWAT hypertrophy (Figure 14F). However, expression of 
these inflammatory markers was not correlated to measures of individual fatty 
acids. This correlation exemplifies the utility of this HFD series which produces a 
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range of responses, allowing for correlational analyses across many 
intermediates.   
 
Figure 15: Butter HFD increases expression of some inflammatory markers in 
SWAT. Mean SWAT expression of A) Tnf-α, B) IL-6, and C) IL-1β from mice which 
consumed the indicated HFD for 12 weeks. Gene expression is normalized to 
expression of β-actin. (n=5; one-way ANOVA multiple comparisons to SD 
 
 
Gene expression of inflammatory cytokines was also characterized in 
SWAT. None of the diets resulted in a significant change in change in Tnf-α 
expression (Figure 15A). However, both Butter and Cocoa diets resulted in 
increased expression of IL-6 in the SWAT (Figure 15B). The Butter diet also 
resulted in significantly increased expression of IL-1β compared to SD (Figure 
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15C). None of the SWAT expression of these inflammatory markers correlated 
significantly to measures of adipose expansion (data not shown). 
 
Figure 16: VWAT expression of fibrotic markers is primarily increased with 
consumption of 60% lard diet. VWAT expression of A) Tgf-β1, B) Ctgf, C) Col1a1, and 
D) Col6 in mice which had eaten one of HFDs for 12 weeks. Gene expression is 
normalized to expression of β-actin. (n=5, * one-way ANOVA multiple comparisons to 
SD, # unpaired t-test to SD) 
 
 
In addition to inflammatory markers, Tgf-β1149, Col1a1, Col3a1, and 
Col6150 were selected as fibrotic genes which are strongly upregulated with 
obesity. VWAT expression of Tgf-β1 was only increased in mice consuming the 
60% Lard diet. Interestingly, the 45% Lard diet resulted in the opposite change, 
with a slight but significant decrease in Tgf-β (Figure 16A). VWAT expression of 
Ctgf was significantly increased in mice which ate the Coconut diet (Figure 16B). 
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Similar to VWAT Tgf-β1 expression, VWAT expression of Col1a1 was only 
significantly increased on the 60% Lard diet when compared directly to SD 
(Figure 16C). Finally, VWAT expression of Col6 was increased in the Safflower 
and HO Safflower diets, although it was also increased in both the 45% and 60% 
Lard diets when they were compared directly to SD (Figure 16D). These results 
show that while expression of several of these genes is increased in the context 
of the 60% lard HFD, the gene expression is not affected in many other diets 
which also induced obesity.  
 
Figure 17: Dietary fat source has varying effects on SWAT expression of fibrotic 
markers. SWAT expression of A) Tgf-β1, B) Ctgf, C) Col1a1, and D) Col6 in mice which 
consumed indicated HFD for 12 weeks. Expression is normalized to β-actin expression. 





Like VWAT, Tgf-β1 expression was not significantly changed in the SWAT 
(Figure 17A). However, both Butter and Cocoa diets resulted in increased SWAT 
expression of Ctgf compared to SD (Figure 17B). Additionally, SWAT expression 
of Col1a1 was increased compared to SD on the Fish, Palm, Cocoa, and HO 
Safflower diets (Figure 17C). Finally, Palm, Lard, and HO Sunflower diets 
resulted in increased expression of SWAT Col6 (Figure 17D). Like the VWAT, 
this data shows that gene expression is influenced by the dietary fat type and not 
necessarily by the obesity status of the mouse.  
 
Discussion 
 Dietary fats have been well studied for their impacts on adipose 
homeostasis and effects on systemic metabolic health151. Using a screen of 12 
HFDs has invoked many intermediate responses in adiposity and gene 
expression, allowing for a more nuanced understanding of WAT expansion and 
function. While our identified correlation between VWAT adiponectin expression 
and VWAT adipocyte diameter was expected given published findings47,48, the 
depot specificity of this finding to the VWAT was particularly interesting. As 
female mice lack the depot-specific adipogenic response to HFD observed in 
male mice131, one could study whether adiponectin expression correlates to 
hypertrophy in both depots in females as well.  
The negative correlation between VWAT adiponectin expression and 
palmitate is consistent with findings that palmitate inhibits adiponectin 
transcription152. However, this publication focused on the study of 3T3-L1 cells in 
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vitro, and therefore the in vivo data presented here represents a valuable 
contribution to the field. If further work will be needed to determine if these 
measures are casually linked or are merely correlational. However, a potential 
hypothesis is that prolonged consumption of palmitic acid is a signal to decrease 
VWAT adiponectin expression during obesity. Finally, adiponectin is also present 
in oligomers of varying sizes, and the high molecular weight form of adiponectin 
is negatively associated to diabetes153. Further work will be needed to determine 
whether these variations in adiponectin expression also affect dynamics of 
adiponectin oligomerization. 
The identified correlation between VWAT leptin expression and adipocyte 
formation was unexpected and novel given the expectation that leptin is highly 
linked to adipocyte size138. While this correlation was surprising, it is consistent 
with the published observation that plasma leptin levels do not increase until 
several weeks after HFD consumption154. This time scale would be longer than is 
needed to alter adipocyte hypertrophy, which can be affected with several hours 
of fasting and refeeding155,156. In considering how adipose hyperplasia relates to 
leptin production, two possibilities are that an increase in existing adipocytes 
results in greater leptin production or that newer adipocytes produce greater 
quantities of leptin. Another intriguing question would be to interrogate whether 
adipocyte formation during developmental WAT establishment is a driver of the 
postnatal surge in plasma leptin157. Interestingly the timing of the postnatal leptin 




 I identified that VWAT expression of Tnf-α correlated negatively with two 
measures of hyperplasia—proliferating APs at the onset of diet and BrdU-labeled 
adipocytes after several weeks of HFD consumption. These data are consistent 
with the observations that Tnf-α treatment inhibits the differentiation of 3T3-L1 
cells into mature adipocytes159 but provides in vivo findings to support these 
published in vitro results. As VWAT Tnf-α expression did not correlate to my third 
measure of hyperplasia, assessed using the AdiCre-ER/mTmG mouse model, 
this relationship could be driven by AP proliferation and activation. This 
correlation was only observed in the VWAT, rather than the SWAT, consistent 
with the male VWAT being a tissue capable of an adipogenic response to HFD. 
Due to the adipogenic response in female SWAT and VWAT13, studying Tnf-α 
expression in female mice that consumed our HFD screen could distinguish 
whether this relationship is depot specific or primarily dependent on AP 
activation. 
 While these data show that dietary fats impact expression of Tnf-α, IL-6, 
and IL-1β, no dietary fatty acids correlated with expression of these inflammatory 
markers. Additionally, although many of these HFDs induced significant fat mass 
gain in the mice (Figure 1: Dietary fat source determines whether VWAT expands 
primarily via hypertrophy or hyperplasia. A) VWAT AP proliferation in mice fed SD or 
pair-fed HFD mice for 7 days. (n=5; unpaired t-test; experiment conducted by 
Christopher Church) B) AP proliferation in SWAT and VWAT normalized to the SD-fed 
VWAT proliferation. Mice were fed the indicated HFD for 7 days. (n=5-2; experiment 
conducted by Jennifer Kaplan) C) VWAT weights of mice which consumed the indicated 
HFD for 12 weeks (n=4-5; measured by Jennifer Kaplan) D) Quantification of newly 
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formed adipocytes from AdiCre-ER/mTmG mice. Mice were injected with tamoxifen then 
given indicated HFD for 8 weeks. (n=3-18) E) Quantification of VWAT BrdU-labeled 
adipocyte nuclei. Mice were given indicated HFD with BrdU water for one week. BrdU 
water was then removed, and mice continued to consume indicated diet for a total of 12 
weeks. (n=4-5). F) Mean VWAT adipocyte volume from mice which consumed the 
indicated HFD for 12 weeks. (n=4-5). Correlations between VWAT mass and G) average 
VWAT adipocyte diameter for each diet and H) average rate of adipocyte formation for 
each diet. (Significance calculated by one-way ANOVA multiple comparisons to SD or 
Spearman correlation)C, Figure 2: SWAT lacks an adipogenic response to HFDs 
and expands primarily via hypertrophy. A) SWAT mass after 12 weeks of diet 
consumption. (n=5; measured by Jennifer Kaplan) B) Quantification of newly formed 
SWAT adipocytes in AdiCre-ER/mTmG mice after 8 weeks of HFD consumption. (n=3-
18) C) Quantification of proportion of BrdU-labeled SWAT adipocyte nuclei in mice which 
ate diet for 12 weeks. (n=4-5) D) Mean SWAT adipocyte volume after 12 weeks of 
consuming indicated HFD. (n=4-5). Correlations between SWAT mass and E) SWAT 
adipocyte diameter and F) SWAT adipocyte formation in AdiCre-ER/mTmG mice. 
(Significance calculated by one-way ANOVA multiple comparisons to SD or Spearman 
correlation)A), few significantly altered expression of these inflammatory genes. 
These results were unexpected, especially as these markers were selected as 
likely to be responsive to the obese state. There are varying states of obesity that 
are less associated with disease, as observed by the existence of the 
“metabolically healthy obese” phenotype160. While understanding of this state is 
progressing, it importantly indicates that expansion of WAT does not inevitably 
lead to tissue dysfunction. Additionally, while the 60% lard HFD (Research Diets, 
Inc; D12492) has been extensively studied (as evidenced by thousands of 
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citations), consumption of animal fats has declined over time161. My data 
highlights the need to study obesity as it is induced by other fats as these 
sources may result in differing phenotypes. 
 Finally, in characterizing expression of fibrotic markers, many of the diets 
failed to induce a significant change in gene expression, with the exception of the 
60% lard diet when compared directly to the Chow diet. Like the inflammatory 
gene expression data, the failure of these HFDs to upregulate expression of 
these fibrotic markers was unexpected given the fat mass gain while consuming 
these diets, which was expected to drive fibrosis. This observation could be due 
to the larger quantity of fat in this diet, and perhaps greater changes would be 
observed if this HFD series contained 60% fat as well. However, these findings 
also suggest that further work studying how various dietary fats impact WAT 
function is needed. 
 For this study, the use of a series of matched HFDs was instrumental in 
inducing moderate responses that could be correlated to assess how 
mechanisms of WAT expansion related to expression of adipokines and markers 
of inflammation and fibrosis. Future work may focus on the mechanisms of these 
relationships. Unexpectedly, the expression of several inflammatory and fibrotic 
genes was not changed during consumption of several of these diets. Further 
work is needed to understand the connections between dietary fatty acids, 






The development of the 3T3-L1 cell line enabled the study of signaling 
and transcriptional pathways involved in adipogenesis56,162,163. Despite this a 
detailed understanding of the molecular mechanisms driving adipogenesis in vivo 
was lacking. Jeffery et al. provided this necessary in vivo study, establishing that 
diet-induced adipogenesis is specific to the VWAT in male mice and that diet-
induced adipogenesis is dependent on Akt2 signaling, in a mechanism specific to 
obesity96. However, more work was needed to identify the nutritional signal which 
activated this pathway.  
 In the work presented here, dietary oleic acid is identified as driver of AP 
proliferation and differentiation. This role of oleic acid in adipogenesis is 
noteworthy, given its high prevalence in the Mediterranean diet which is 
associated with longevity. However, as previously discussed, the Mediterranean 
diet is associated with many other lifestyle choices which are also associated 
with improved health, such as high vegetable intake and frequent exercise111. 
Additionally, expansion of the adipose tissue in the face of increased dietary fat 
consumption sequesters lipids away from other peripheral tissues where lipid 
deposition can lead to insulin resistance119. More work is needed to study how 
dietary oleic acid and its signaling impact metabolic health. This HFD series will 
continue to be an exciting tool to study these relationships and the connections 
between other dietary fatty acids and physiology. 
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Leveraging in vitro model with primary APs, we determined that this oleic 
acid signaling is dependent on Akt2 signaling and activation of lipogenesis. To 
identify the mechanisms of oleic acid signaling on APs, I initially interrogated the 
role of the free-fatty acid receptors Gpr120 and Gpr40. Through a variety of 
experiments, I did not observe any effect of these receptors on AP activation or 
adipogenesis. These results contrast with published work citing a role for ciliary 
Gpr120 in the differentiation of 3T3-L1 cells164. Although further work would be 
needed to characterize the discrepancies between these findings, and while this 
publication utilizes in vivo models to identify the role of cilia in APs for 
differentiation, the data showing the role for Gpr120 is performed entirely in the 
3T3-L1 cell line. While these cells are useful for larger screens and more high-
throughput experiments, validation using primary cells or an in vivo model would 
have led to more robust conclusions. 
Building on our observation that LXRα downregulation represents a major 
change in gene expression during early HFD consumption, I used a combination 
of in vitro and in vivo models to demonstrate that oleic acid reduces LXR 
signaling. In addition, I identified LXRα phosphorylation as a modulator of in vivo 
AP proliferation during HFD consumption. In using mice with a serine-to-alanine 
point mutation in LXRα, I observed that VWAT APs demonstrated enhanced diet-
induced proliferation, while SWAT APs had increased basal proliferation. Given 
more time, further work to assess the role of LXRα phosphorylation on in vivo AP 
differentiation would be valuable. One could determine whether these mice also 
have enhanced adipocyte formation, either during the SD-fed state or during 
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HFD consumption. Interestingly, a whole-body knockout of LXRα resulted in 
increased SWAT leptin expression during SD consumption, consistent with the 
hypotheses that LXRα plays a role in basal SWAT adipogenesis and that leptin 
expression is driven by adipocyte formation.  
There is also a need to study the role of LXRα in human APs. Activation of 
LXRα in TH1 cells results in increased expression of aP2, a characteristic protein 
of adipocytes. The aP2 promoter was also found to contain an LXRα response 
element165. Little is known about the role of LXRα phosphorylation in human 
pathology, beyond the observation that phosphorylated LXRα is present in 
human liver166. Further work is needed to determine the role, if any, of LXRα in 
human adipogenesis. However, the ability of oleic acid to increase adipogenesis 
of human APs is promising for further study of this mechanism in human 
samples. 
In addition to mechanisms of adipogenesis, I also used this HFD series to 
characterize how dietary fats affect expression of a subset of inflammatory and 
fibrotic markers. While many studies have contrasted a HFD to a low-fat diet, 
using a series of HFDs provides a more complex context rather than comparing 
the extremes of lean and obese states. This approach is particularly useful in 
comparing how mechanisms of WAT expansion are related to gene expression, 
as I can analyze several intermediate responses, allowing for stronger 
conclusions. This strategy led to the surprising discovery that VWAT leptin 
expression is closely correlated to several measures of hyperplasia. Further work 
will be needed to determine whether this increased leptin expression is due to 
65 
 
more adipocytes present in the tissue or whether the newly formed adipocytes 
have increased expression of leptin. Additionally, I was surprised by the temporal 
disparity in the correlation between AP proliferation for a subset of the diets and 
VWAT leptin expression. Given that AP proliferation is quantified after one week 
of HFD consumption and leptin expression was quantified after 12 weeks, it 
suggests that AP proliferation early in HFD may be predictive of eventual leptin 
expression. However, this relationship is limited to diets that also induced high 
rates of adipocyte formation, so further studies to understand of WAT response 
to long-term consumption of the diet will be needed.  
Finally, I also used this HFD series to quantify gene expression of a 
subset of inflammatory and fibrotic markers. This work demonstrates the 
importance of dietary fats on WAT gene expression and function. Obesity 
primarily driven by hypertrophy is considered to be linked to WAT inflammation 
and cell death. However, my data did not find strong correlations between 
expression of these markers and hypertrophy. While these results could be 
driven by the lower quantity of fat in my 45% HFD series (the classic HFD 
contains 60% fat, primarily lard), they also challenge the idea that hypertrophy 
and inflammation are so consistently linked. While inflammation has been well 
studied using the 60% lard-based HFD167,168, these HFDs based on alternatives 
fats provide a different context for the obesity. Given the diverse diet currently 
consumed by humans and the declining prevalence of lard in the diet 161, these 




The role of fibrosis in obesity is disputed; it is unclear fibrosis provides a 
check on ballooning adipocyte size or whether it is a marker of a pathological 
tissue45,169. Like the expression of the inflammatory markers, expression of the 
fibrotic markers was not significantly increased, even in diets which induced 
obesity and hypertrophy. However, some of the markers were increased on the 
lard HFDs, particularly the 60% lard HFD. Again, these findings highlight the 
need to study obesity in a more physiologically relevant context. While many of 
the HFDs induced obesity, the mechanisms of WAT expansion (whether primarily 
through hypertrophy or hyperplasia) differed. Further work would be needed to 
characterize how WAT gene expression and homeostasis differs on these diets 
and what effects these differences play in systemic metabolic health.  
This work utilized a HFD series to identify a novel mechanism that 
regulates obesogenic responses and in vivo AP proliferation. This study also 
allowed me to characterize the relationships between obesity and inflammation 
and fibrosis. These findings further our understanding of the nutritional signals 
that drive in vivo adipogenesis and the relevance of dietary fats to WAT function. 
Further work is needed to define how these nutritional signals relate to measures 







Figure 18: Quantification of adipogenesis in female mice. BrdU pulse-chase 










All experiments using animals were conducted according to guidelines by 
Yale University’s Institutional Animal Care and Use Committee (IACUC). Mice 
used for these studies were on the C57BL/6J background, with wild-type animals 
purchased from Jackson Laboratories. Adiponectin-CreER/mTmG mice were 
bred in in the Yale Animal Resource Center from Adiponectin-CreER mice gifted 
by E. Rosen (Beth Israel Deaconess Medical Center, Boston, MA, USA) and 
mTmG B6.129 (Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J 
purchased from Jackson Laboratories. Atk2-/- mice were a kind gift from W. 
Sessa (Yale University, New Haven, CT, USA). PdgfRα/Akt2flox/flox mice were 
bred in the Yale Animal Resource Center from PdgfRα-Cre mice purchased from 
Jackson Laboratories and Akt2flox/flox mice kindly gifted by M. Birnbaum 
(University of Pennsylvania, Philadelphia, PA, USA) and mediated by K. Martin 
(Yale University, New Haven, CT, USA). LXRα S196A mice were housed at New 
York University, and fixed cells were kindly provided by Dr. Michael Garabedian.  
Unless otherwise noted, experiments were started using male mice aged 
6-8 weeks old. We use the terms VWAT to refer to the perigonadal visceral 
adipose tissue and SWAT to refer to the inguinal subcutaneous adipose tissue. 
Standard diet (SD) is purchased from Harlan Laboratories (2018S), and the 60% 
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lard-based diet was purchased from Research Diets, Inc(D12492). The 45% kcal 




Table 1: 45% kcal high-fat diets used for screen 
Fat Catalog # 
Lard D12451 
Olive Oil D06022403 
Coconut Oil D05122301 
Fish Oil D03022403 
Palm Oil D07081501 
Safflower Oil D02062102 
Butter D06022405 
Cocoa Butter D11112703 
High Oleic Sunflower Oil D07062503 
High Oleic Safflower Oil D05122103 
Soybean Oil D05042003 
Peanut Oil D16010705 
 
Fatty acids or tri-oleate (Sigma Aldrich, T7752) were added to the SD to 
45% kcal fat. For in vivo oleic acid infusion experiments, jugular catheters were 
implanted into the right vein when mice were 8 weeks old. Oleic acid (20 mM) or 
vehicle (0.5% fatty acid free BSA in saline) were infused just before the dark 
cycle for 5 days.  
For in vivo BrdU experiments lasting one week, mice were given 0.8 
mg/mL brdU in drinking water with fresh solution made every other day. For BrdU 
pulse-chase experiments, BrdU was administered at 0.4 mg/mL in drinking water 
for one week and then removed and normal water provided.  
To treat mice with T0901317, mice were given conditioning injections 
using vehicle, or medium chain triglycerides (MCT) daily for 4 days. Mice were 
then given vehicle or 50 mg/kg of T0901317 daily for 3 days, along with HFD 
before being sacrificed and processed for BrdU analysis.  
 
AdiponectinCre-ER/mTmG pulse chase experiment 
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This experiment was performed as previously described19. In brief, at 8 
weeks of age, Adiponectin-CreER/mTmG mice were given daily injections of 
tamoxifen in vegetable oil at 50 mg/kg for 5 days. The mice were then given a 
week to recover and then were fed the stated diet for 8 weeks. At the end of 8 
weeks, the mice were sacrificed, and their SWAT and VWAT were mounted on 
slides. The tissues were imaged using confocal microscopy, and the proportion 
of red to green adipocytes was quantified.  
 
Immunohistochemistry and adipocyte size quantification 
For the BrdU pulse-chase and adipocyte sizing experiments, adipose 
tissue was dissected and prepared for paraffin embedding as previously 
described170. In brief, tissues were dissected and fixed in zinc formalin for 24-48 
hours. The tissues were then washed twice in PBS and incubated overnight in 
70% ethanol. The tissues were then incubated in 75%, 95%, and 100% ethanol, 
and Citrisolve (Fisher Scientific, 22143975). The tissues were incubated in 
melted paraffin before finally being embedded. Paraffin blocks were sectioned by 
Yale Pathology Tissue Services.  
For adipocyte sizing, tissue sections were stained with Masson’s 
Trichrome stain and imaged using by Yale Pathology Tissue Services. To 
quantify adipocytes sizes, sections were systemically imaged and processed 
using a Cell Profiler pipeline adapted from a previous publication 170. At least 300 
adipocytes were quantified from each mouse. To correct for the fact that imaging 
random cross sections of the roughly spherical adipoctyes was not likely to 
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capture the adipocyte at its greatest diameter, a correcting program was kindly 
written by Dr. Taylor Malone at Yale University. This program was adapted from 
the program StripStar, which calculates a corrected distribution of spheres from a 
measured distribution of sectional areas. The original StripStar program 
developed for rock grain-size. The histogram of observed cell radii is compared 
to a theoretical distribution where cells sizes are uniformly distributed. The 
corrected histogram is calculated starting from the largest observed cell size, 
iteratively "stripping off" observed cells until all cells are accounted for. A 
complete desctription of the calculation can be found in Heilbronner et. al171. 
For the BrdU pulse-chase experiment, sections were deparaffinized as 
previously published 170. In brief, the slides were incubated in Citrisolve, 100%, 
95%, 70% ethanol and PBS. Sections were surrounded with a PAP pen and 
blocked with a 2% BSA in PBS solution. Sections were stained using rat anti-
BrdU (Abcam, 6326; 1:300) and rabbit anti-caveolin-1 (Cell Signaling 3238 
1:400) and washed three times in PBS. Sections were then stained with anti-
rabbit Rhodamine-X-Red (Jackson Immunoresearch, 111-295-144; 1:250) and 
anti-rat Alexa Fluor 488 (Jackson Immunoresearch, 112-545-167; 1:250) 
secondary antibodies and washed three times in PBS. DAPI Fluoromount-G 
mounting media (Southern Biotech) was then used, along with a coverslip which 
was sealed with nail polish. Sections were then imaged with confocal 
microscopy. 
To quantify phospho- LXRα in APs, sections were deparaffinized as 
described. After blocking with 2% BSA in PBS, cells were incubated overnight 
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with rat anti-Sca1 (BioLegend, 122501; 1:50) and rabbit anti-phospho- LXRα 
(Garabedian lab, NYC; 1:50) at 4ºC. Sections were washed and incubated with 
donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch, 1:800) for 2 hours at 
room temperature. Seconds were then washed three times in PBS. Tyramide 
SuperBoost Kit Alex Fluor 594 was used to augment the phosphor- LXRα signal 
(ThermoFisher Scientific, B40944). Sections were incubated with poly-HRP-
conjugated secondary antibody at room temperature for 1 hour. They were then 
washed three times with PBS and incubated with tyramide working solution for 5 
minutes at room temperature. Sectionss were washed three times with PBS 
when incubated at room temperature with DAPI (1:1000) for 15 minutes. They 
were then washed three times with PBS and mounted for imaging.  
 
Flow cytometry  
Flow cytometry for analysis, isolation of APs, and BrdU quantification were 
performed as previously described 19,64. In brief, adipose tissue was dissected, 
minced, and digested using a 0.8 mg/mL collagenase II (Worthington 
Biochemical Corporation LS004176) dissolved in a solution of 3% BSA in Hank’s 
Balanced Salt Solution (HBSS; Sigma Aldrich H8264). Cells were placed in a 
shaking water bath at 37ºC for one hour, shaken by hand, then continued to 
shake for 15 minutes. If cells were being sorted, they were first filtered through a 
100 μm filter. Cells for all experiments were filtered through a 40 μm filter. If cells 
were being analyzed or sorted, they were stained using antibodies for CD45 
APC-eFluor780 (eBioscience, 47-0451-80; 1:1000 for sorting, 1:500 for BrdU 
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analysis), CD31 PE-Cy7 (eBioscience, 25-0311-82; 1:500), CD29 Alexa Fluor 
700 (BioLegend, 102218; 1:400), CD34 Alexa Fluor 647 (Biolegend, 119314; 
1:400), Sca1 Pacific Blue (BD Biosciences, 560653; 1:400), and CD24 PerCP-
Cyanine 5.5 (eBioscience, 45-0242-80; 1:250) for 20-30 minutes on ice. Cells 
were sorted with a BD FACSAriaII and analyzed using a BD LSRII analyser and 
BD FACS Diva software. 
If the cells were being analyzed for BrdU quantification, after digestion and 
filtration, they were prestained with antibodies for CD45 APC-eFLuor780, CD31 
PE-Cy7, CD29 Alexa Fluor 700 (as listed above), and Sca1 V500 (BD Horizon, 
561228; 1:500) for 20-30 minutes on ice. Cells were then washed, fixed, and 
permeabilized according to the instructions for Phosflow Lyse/Fix and Perm 
Buffer III (BD Biosciences). Cells were then treated with Dnase (Worthington 
Biochemical Corporations, LS002007) in PBS and washed with 3% BSA in 
HBSS. The cells were incubated with anti-BrdU Alexa Fluor 488 or 647 (Phoenix 
Flow Systems, AX647 or AX488; 1:30) overnight, washed, then stained a mixture 
of antibodies for CD45, CD31, CD29 (as listed above), CD34 Alexa Fluor 647 
(listed above) or Brilliant Violet 421 (BioLegend, 119321; 1:400), Sca1 Pacific 
Blue or V500, and CD24 (1:200) for 30 minute at room temperature. Cells were 
then washed and analyzed. 
 To quantify proliferation in LXRα S196A mice, Ki67 was used as a marker 
of proliferation due to BrdU being a restricted substance in the New York 
University mouse facility. To quantify Ki67 in APs, after antibody staining, WAT 
was digested and incubated in Phosflow Lyse/Fix as discussed for the BrdU 
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quantification. Cells were then washed twice in Intracellular Staining 
Permeabilization Wash Buffer (BioLegend, 421002). After washing, cells were 
incubated with Anti-Ki67 FITC (eBioscience, 11-5698-80; 1:50). Cells were 
washed twice again in Permeabilization Wash buffer and resuspended in 3% 
BSA in HBSS for analysis.  
 
Isolation of human APs 
 Consent and experimental protocols to isolate human APs were reviewed 
and approved by the Yale Internal Review board (HIC protocol number 
1109009063). Samples were subcutaneous and abdominal adipose tissue 
regarded as waste materials from bariatric surgeries or elective 
abdominoplasties. Samples were stored in sterile saline solution until processing. 
 Tissues were washed with Krebs Ringer Phosphoate (KRP) solution 
containing 0.127 M Nacl, 5 mM KCl, 2 mM sodium phosphate dibasic, and 8 mM 
sodium phosphate monobasic. Tissues were minced, washed in KRP solution, 
and centrifuged to separate red blood cells. Samples were then digested in KRP 
solution with 3% FBS and collagenase type II for 75 minutes in a shaking water 
bath at 37ºC. Samples were then filtered and washed with KRP and 3% chelexed 
fetal calf serum (FCS). The floating layer of adipocytes was removed. Remaining 
cells were then stained using antibodies for CD235 PE-Cy5 (BioLegend, 
306605), CD45 Pacific Blue (Biolegend, 368539), GP38 PE (BioLegend, 
337003), CD13 APC-Cy7 (BioLegend, 301709), CD34 APC (eBioscience), CD90 
(BD Biosciences). Cells were then washed with KRP with 3% chelexed FCS.  
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 Cells were then selected for GP38 using EasySep Human PE positive 
selection kit (Stem Cell Technologies, 17664). Cells were incubated with the PE 
selection cocktail for 15 minutes, then incubated with the magnetic beads and 
placed in the magnet. Cells were eluted up to 2 times using KRP with 3% 
chelexed FCS. Cells were then sorted using the following marker scheme: CD45-
; CD235-, CD90+, GP38+, and CD34+.   
 
Lipidomic analysis of diet, plasma and WAT 
Plasma and WAT for fatty acid analysis was harvested at 6am after ad 
libitum feeding. Samples were analyzed at the Mouse Metabolic Phenotyping 
Center at the University of Cincinnati. Samples were saponified and methylated 
for analysis of GC mass spectrometry. Retention times were compared to known 
standards. Fatty acid methyl esters were separated and quantified by gas-liquid 
chromatography with a Hewlett-Packard 68900 series II gas chromatograph, 
using an Omegawax column (Supelco) and flame ionization detector.  
 
Cell transplant assay 
Cell transplants were performed as previously described172. In brief, 
SWAT and VWAT APs were harvested and pooled from several mice as detailed 
above. APs were rinsed in PBS and resuspended in PBS. Recipient mice were 
anesthetized with Isothesia (Covetrus, 029405) when aged 4 weeks old. At least 
0.5 million APs were injected into the tip of one recipient VWAT depot. Recipient 
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mice were allowed to recover for 2 weeks and then placed on HFD for 1 week. 
They were then sacrificed and analyzed for BrdU incorporation into APs.  
 
In vitro differentiation of primary APs and 3T3-L1 cells and Oil Red O assay 
Primary APs were isolated as described above. They were cultured in 
growth media consisting of DMEM (ATCC, 30-2002) supplemented with 1% 
penicillin/streptomycin (Sigma Aldrich, G1146) and 10% fetal bovine serum (Life 
Technologies). Upon reaching confluence, media was not changed for 48 hours. 
To differentiate the APs, the media was supplemented with 0.1 μg/mL insulin 
(Sigma Aldrich I-5500) and maintained in this solution for 7 days with media 
changings every other day. If cells were being differentiated in the presence of a 
fatty acid, the fatty acid was conjugated to fatty acid free BSA (Sigma Aldrich 
7030) and added to the differentiation media at 100 μM.  
 3T3-L1 cells were maintained in the same growth media as primary APs. 
They were passaged when nearly confluent by rinsing with PBS and detaching 
with 0.05% Trypsin/EDTA (Life Technologies, 25300054). When nearly confluent, 
experimental cells were differentiated with an adipogenic cocktail (MDI) 
consisting of 0.1 µg/mL insulin, 30 µg/mL 3-isobutyl-1methylxantine (Sigma 
Aldrich, 15879), and 0.1 µg/mL dexamethasone (Sigma Aldrich, D-4902). After 
48 hours, media was maintained in 0.1 µg/mL insulin and changed every other 
day for 7 days. 
To quantify accumulated lipid, cells were washed twice with PBS and fixed 
in a solution containing 0.2% glutaraldehyde and 2% formaldehyde in PBS. The 
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cells were then washed twice with PBS, twice with water, and briefly with 60% 
isopropanol. After the washes, the cells were stained with a mixture of 60% Oil 
Red O (Electron Microscopy Sciences 26503-02) and 40% water and then 
washed briefly with 60% isopropanol and twice with water. The cells were 
imaged and left in water overnight. The next day, the cells were dried for several 
hour,s and then the dye was extracted using a solution of 4% NP40 in 
isopropanol. The absorbance of the extraction solution was then analyzed on a 
spectrophotometer at 500 nm.  
Primary APs treated with inhibitors were treated 2 hours before 
differentiation. Cells were treated with Glucose Transporter Inhibitor II 
(Calbiochem, 10 µM) or C75 fatty acid synthase inhibitor (Sigma Aldrich; 100 
µM). Cells were treated with 5 μm T0901317 in DMSO. 
 
Transfection and luciferase reporter assay 
3T3-L1 cells were cultured in a 48 well plate to nearly confluent before 
transfection. Cells were transfected using Lipofectamine 2000 Transfection 
Reagent (LifeTechnologies, 11668019) in OptiMEM (LifeTechnologies, 
31985070). Cells were transfected with Cignal LXR Reporter Kit (Qiagen, 
336841; 500 ng) for 24 hours. Media was then changed to treatment media. 
LXR activity was quantified using the Luciferase Assay System (Promega, 
E1500) according to the protocol. In brief, cells were lysed and spun at 12,000 g 
for 2 minutes at 4ºC. Sample was then mixed with luciferase assay substrate, 




Isolation of RNA and real time qPCR 
If analyzing gene expression in tissue, tissues were dissected, frozen in 
liquid nitrogen and stored at -80˚C. The tissues were then homogenized in Trizol 
LS (Life Technologies 10296010). If analyzing gene expression in cells cells, 
cells were washed in PBS and then suspended in Trizol LS. If not being 
processed immediately, the cells were frozen in Trizol LS at -80˚C. 
RNA from both tissues and cells was harvested using a Direct-zol RNA 
Miniprep kits (Zymo Research, R2051) and quantified using a nanodrop 
spectrophotometer. RNA was converted to cDNA using a cDNA Reverse 
Transcription kit (Applied Biosystems, 4368814). qPCR was performed with 
KAPA SYBR FAST for LighCycler480 (Kapa Biosystems KK4611) on a 
LightCycler 480 Real Time PCR system (Roche). 
 
Immunoblots 
For Akt2 immunoblots, primary APs were lysed using 1% IGEPAL with 
protease and PhosStop phosphatase inhibitors (Roche). For LXRα immunoblots, 
protein was lysed using a mixture of SDS (0.645%), sodium deoxycholate 
(6.45%), Triton X100 (6.45%) supplemented with 11.5 mM sodium 
pyrophosphate, 11.5 mM β-glycerophosphate disodium, and protease and 
PhosStop phosphatase inhibitors. Protein was quantified using Pierce BCA 
protein assay kit (Life Technologies, 23225). Protein was incubated with NuPage 
2X Sample Buffer (ThermoFisher Scientific, NP0007) and Sample Reducing 
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Agent (ThermoFisher Scientific, NP0009). Western blots for Akt2 were run on 
10% polyacrylamide gels, while Western blots for LXRα were run on 10% Bis-
Tris gels. Protein was then transferred to PVDF membranes using the Invitrogen 
NuPage system.  
For Akt2 immunoblots, membranes were stained with rabbit anti-Akt2 (Cell 
Signaling, 3063; 1:1000) or rabbit anti-phospho-Akt2 (Cell Signaling, 8599; 
1:500) in tris-buffered saline with 0.1% Tween-20 (TBST). Membranes were then 
incubated with goat anti-rabbit-HRP secondary antibody (Jackson 
Immunresearch, 211-032-171; 1:10,000) and developed with SuperSignal West 
Pico Chemiluminescent Substrate (Pierce).  
For LXRα immunoblots, membranes were blocked with 5% BSA TBST. 
They were incubated with rabbit anti-phospho- LXRα kindly provided by Dr. 
Michael Garabedian’s lab at New York University (1:2000) or rabbit-anti LXRα. 
They were then incubated with goat anti-rabbit-HRP (ThermoFisher Scientific, 
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